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RESUMEN
GPR55 es un receptor huérfano acoplado a proteinas G que, según publicaciones recientes, podría 
ser activado por lisofosfatidilinositol y determinados cannabinoides. Aunque se conoce poco todavía 
sobre su función fisiológica, existen evidencias que indican que podría desempeñar un papel importan-
te en la regulación del metabolismo óseo o el control del dolor inflamatorio, por ejemplo. En esta Tesis 
hemos estudiado el papel de GPR55 en la fisiopatología del cáncer. Nuestros resultados muestran que 
GPR55 se expresa en tumores de distintos orígenes y que su expresión es significativamente más alta 
en tejidos transformados frente a tejidos sanos. Dicha expresión se correlaciona además con una mayor 
agresividad tumoral y un peor pronóstico de los pacientes. Los estudios que hemos realizado demues-
tran que GPR55 proporciona a las células cancerígenas una serie de ventajas adaptativas que podrían 
explicar la mayor agresividad de los tumores que expresan niveles elevados de GPR55. Primero, he-
mos demostrado que GPR55 induce la proliferación de células tumorales a través de la activación de 
la cascada de señalización ERK/MAPK, tanto en cultivos celulares como en modelos in vivo de cáncer. 
Esta activación promueve el crecimiento tumoral en modelos animales basados en  xenografts y en el 
modelo de carcinogénesis química en piel de ratón. Segundo, hemos observado que la expresión de 
GPR55 favorece otra serie de características estrechamente relacionadas con la progresión tumoral en 
general y la generación de metástasis en particular. Así, GPR55 promueve el crecimiento independiente 
de anclaje, la migración e invasión de células tumorales a través de la activación de proteínas Gq y la 
generación in vivo de metástasis en pulmones. 
Por último, hemos investigado si GPR55 está implicado en el efecto bifásico de los cannabinoides 
sobre la proliferación de células tumorales. Nuestros resultados muestran que GPR55 participa en la 
respuesta pro-proliferativa que induce el THC a bajas concentraciones, y sugieren que dicha acción po-
dría estar mediada por la interacción funcional entre GPR55 y el receptor clásico de cannabinoides CB1.
En conjunto, estos resultados sugieren que GPR55 podría ser un nuevo marcador con valor pronós-
tico y una nueva diana terapéutica en oncología.
 
ABSTRACT
GPR55 is an orphan G protein-coupled receptor that has been proposed to be engaged by lysophos-
pholipids and cannabinoids. Though little is known about the physiological function of GPR55, emerging 
evidences point to important regulatory functions throughout the body. In this Thesis we studied the 
role of GPR55 in cancer physio-pathology. We found that GPR55 is expressed in human tumors from 
different origins, and that this expression is higher in the transformed tissues as compared with the 
corresponding non-transformed tissues and correlates with tumor aggressiveness. Our results show 
that GPR55 expression confers a series of adaptative advantages on cancer cells that make them more 
aggressive. First, we demonstrate that GPR55 drives cancer cell proliferation, through activation of the 
ERK/MAPK cascade, both in cell cultures and in vivo, which results in the promotion of tumor growth in 
xenograft-based and chemical-carcinogenesis animal models of cancer. Second, we show that GPR55 
expression favors another set of capabilities that are intimately related to tumor progression in general 
and the generation of metastasis in particular. Thus, GPR55 promotes anchorage-independent growth, 
migration and invasion of cancer cells in culture through activation of Gq proteins and the generation of 
lung metastasis in vivo. 
Finally, we investigated if GPR55 is involved in the biphasic effect of cannabinoids on cancer cell 
proliferation (low concentrations producing pro-proliferative responses while high concentrations indu-
cing anti-proliferative effects). Our data show that GPR55 modulates the proliferation-inducing response 
produced by low concentrations of cannabinoids, and suggest that this action may be produced by 
functional interaction of GPR55 with the classical cannabinoid receptor CB1. 
Together, our data suggests that GPR55 could be a new biomarker with prognostic value and a the-
rapeutic target in oncology.


INDEX
RESUMEN
SUMMARY
INTRODUCTION
 1. G PROTEIN-COUPLED RECEPTORS
  GPCR structure
  GPCR signaling pathways
  GPCR and cancer
 2. GPR55
  GPR55 pharmacology
  GPR55 signaling pathways
  GPR55 physio-pathology
AIMS
RESULTS AND DISCUSSION
 CHAPTER 1
  The orphan G protein-coupled receptor GPR55 promotes cancer cell
  proliferation via ERK
	 	 	 Supplementary	figures
 CHAPTER 2
  The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in  
  human squamous cell carcinomas
	 	 	 Supplementary	figures
 CHAPTER 3
  The orphan receptor GPR55 confers pro-metastatic advantages on breast   
  cancer cells in vitro and in vivo
 CHAPTER 4
	 	 GPR55	participates	in	the	effect	of	THC	on	cancer	cell	proliferation	via	CB1/  
  GPR55 functional interaction
GENERAL DISCUSSION
CONCLUSIONS
CONCLUSIONES
REFERENCES
1
5
11
13
13
15
17
21
21
26
26
31
35
37
39
47
53
55
65
75
77
91
93
105
115
116
119



Los receptores acoplados a proteínas G (GPCRs) constituyen la superfamilia más numerosa de re-
ceptores celulares. Controlan funciones fisiológicas cruciales, y su disfunción contribuye al desarrollo y 
aparición de muchas enfermedades humanas, incluyendo el cáncer. Por ello, junto con las enzimas, son 
las dianas terapéuticas más comunes. 
Los GPCRs son proteínas integrales de membrana, constituidas por una dominio extracelular N-
terminal, 7 α-hélices transmembranales (7TM) conectadas por 3 loops extracelulares (ECL1, ECL2 y 
ECL3) y 3 loops intracelulares (ICL1, ICL2, ICL3), acabando en un dominio intracelular C-terminal. Los 
GPCRs transforman un estímulo externo (fotones, neurotransmisores, quimioquinas, mediadores lipídi-
cos, hormonas) en señales intracelulares que desencadenarán respuestas biológicas. 
El cáncer es una de las enfermedades más comunes en el mundo, y una de las primeras causas de 
muerte en los países desarrollados. En las últimas décadas su incidencia ha ido aumentado, y estudios 
de la Organización Mundial de la Salud indican un continuo crecimiento en todo el mundo en los años 
venideros. El cáncer es un proceso evolutivo que conlleva una serie de cambios dinámicos en el geno-
ma que producen la acumulación de mutaciones somáticas. Durante este proceso, las células normales 
adquieren diferentes capacidades que desencadenarán su transformación maligna. Estas capacidades 
se conocen como las “Bases del cáncer”. Diferentes estudios han demostrado que los GPCRs pueden 
modular muchos de estos procesos, si no todos. Así, los GPCRs favorecen la proliferación sin control 
de células tumorales, su resistencia a apoptosis y su capacidad invasiva y metastática así como la an-
giogénesis y el control del microambiente tumoral. 
El amplio espectro de acción de estos GPCRs en la fisiopatología del cáncer les convierte en  po-
tenciales dianas terapéuticas. A pesar de ello, solo una pequeña proporción de GPCRs se están explo-
tando clínicamente en la actualidad en oncología. Conocer el mecanismo de acción de los GPCRs en 
la iniciación y progresión tumoral es crucial por tanto para incrementar las herramientas terapéuticas 
basadas en estos receptores. Los GPCRs huérfanos no tienen un ligando endógeno asignado y sus fun-
ciones fisiológicas suelen ser desconocidas, lo que los convierte en una población muy atractiva para 
estos estudios. GPR55 es un receptor huérfano que fue identificado y clonado por primera vez en 1999. 
Distintos estudios sugieren que el L-α-lisofosfatidilinositol (LPI) es el ligando endógeno de GPR55, y que 
diferentes compuestos cannabinoides pueden unirse y activar dicho receptor. GPR55 tiene una expre-
sión muy ubicua, y, aunque se conoce poco sobre su papel fisiológico y mecanismos de acción, se ha 
propuesto que regula diferentes respuestas biológicas en el sistema nervioso central, hueso, sistema 
inmune y vascular, entre otros. 
Diferentes evidencias indirectas sugieren que GPR55 podría estar implicado en la fisiopatología del 
cáncer. Primero, tanto el plasma como el líquido ascítico de pacientes con cáncer de ovario presentan 
altos niveles de LPI, el ligando endógenos propuesto para GPR55, comparado con el plasma y líquido 
RESUMEN
1
ascítico de mujeres sin una patología oncológica. Segundo, GPR55 se une a las proteínas heterotriméri-
cas G12/13 y Gq, que tienen propiedades oncogénicas, y señaliza a través de Rho GTPasas, proteínas que 
controlan la organización del citoesqueleto, la polaridad celular y la migración, procesos intimamente 
relacionados con la progresión tumoral. Por último, determinados cannabinoides (compuestos con pro-
piedades anti-tumorales) pueden activar GPR55.
Considerando todas estas evidencias, la HIPÓTESIS de trabajo de esta Tesis es que GPR55 partici-
pa en el control de la fisiopatología del cáncer. Los OBJETIVOS específicos del trabajo son:
1. Estudiar la expresión de GPR55 en distintos tumores humanos.
2. Investigar el papel de GPR55 en la generación y progresión tumoral.
3. Analizar si GPR55 está implicado en el efecto de los cannabinoides sobre la proliferación de 
células tumorales.
Los RESULTADOS obtenidos en esta Tesis se han dividido en cuatro capítulos:
En el PRIMER CAPÍTULO hemos intentado determinar si GPR55 juega un papel importante en la 
fisiopatología del cáncer. Para ello, primero hemos analizado la expresión de GPR55 en una colección 
de líneas celulares humanas y muestras tumorales de pacientes con cáncer de mama, glioblastoma y 
adenocarcinomas de páncreas. Además, hemos modulado la expresión de GPR55 en diferentes líneas 
tumorales humanas (mediante transfección con un vector que contiene la construcción HA-GPR55 o 
mediante silenciamiento genético del receptor a través de siRNAs específicos) para determinar la impli-
cación de GPR55 en la proliferación de células tumorales in vitro e in vivo. También hemos caracterizado 
los mecanismos moleculares responsables de estos efectos. Hemos observado que la expresión del re-
ceptor está aumentada significativamente en tejido tumoral frente a tejido sano, y en tumores altamente 
agresivos frente a poco agresivos. Además, GPR55 promueve la proliferación de células tumorales 
tanto en cultivos celulares como en modelos animales basados en xenografts a través de la activación 
de la cascada de señalización de ERK/MAPK.
Estos resultados revelan un papel importante de GPR55 en cáncer, y sugieren que podría ser un 
posible nuevo marcador biológico y una nueva diana terapéutica en oncología.
En el SEGUNDO CAPÍTULO, hemos estudiado en más detalle el papel de GPR55 en la generación 
y progresión tumoral. Para alcanzar este objetivo, hemos utilizado el modelo de carcinogénesis quími-
ca en piel de ratón en animales que no expresan el receptor GPR55 y sus correspondientes hermanos 
salvajes. Hemos estudiado el efecto de la ablación genética de GPR55 en la transformación maligna, 
y hemos intentado revelar las bases moleculares de dichos efectos. Finalmente, hemos analizado la 
expresión de GPR55 en diferentes carcinomas de célula escamosa humanos, y hemos intentado deter-
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minar si la expresión de este receptor se correlaciona con marcadores con relevancia clínica. Nuestros 
resultados demuestran que GPR55 induce el desarrollo de tumores de piel en ratón. Así, los ratones 
deficientes en GPR55 son más resistentes a la aparición de papilomas inducidos por DMBA/TPA y a la 
transformación de papilomas en carcinomas que sus hermanos salvajes. Según nuestros resultados, 
GPR55 produce estos efectos pro-tumorales proporcionando una ventaja proliferativa a las células 
tumorales, mediante la sobre-activación de la cascada de señalización ERK/c-Fos/ciclina D1. Nues-
tros resultados también muestran que GPR55 proporciona otras ventajas oncogénicas en las células 
tumorales de piel. Por ejemplo, GPR55 promueve el crecimiento independiente de anclaje, la invasión 
y la tumorigenicidad in vivo, lo que sugiere que este receptor, además de promover el desarrollo tumo-
ral, incrementa la agresividad de los tumores.  Por último hemos observado que GPR55 se encuentra 
sobre-expresado en tumores de piel humanos y en otros carcinomas de célula escamosa con respecto 
al tejido sano del mismo paciente.
En conjunto, estos resultados revelan un papel importante de GPR55 en el desarrollo de tumores de 
piel, y refuerzan la idea de que este receptor podría ser un nuevo marcador y diana terapéutica también 
para carcinomas de célula escamosa. 
En el TERCER CAPÍTULO de esta Tesis, hemos investigado si GPR55 participa en el proceso metas-
tático. Así, hemos analizado el efecto de GPR55 en la migración e invasión in vitro de células de cáncer 
de mama así como el crecimiento de tumores y la colonización en pulmón in vivo. Para estos estudios 
hemos utilizado células tumorales humanas en las que se ha silenciado de manera estable GPR55 (o 
las correspondientes células control) y hemos estudiado los mecanismos responsables de las carac-
terísticas pro-metastáticas inducidas por GPR55. Nuestros resultados demuestran que GPR55 induce 
la migración e invasión de las células de cáncer de mama altamente metastáticas MDA-MB-231. Estas 
células expresan altos niveles de GPR55, y el silenciamiento del receptor reduce su invasividad hacia 
suero y LPI (el ligando endógeno propuesto para GPR55). Más aún, cuando la expresión de GPR55 es 
recuperada, las células tumorales aumentan su invasividad hacia ambos quimioatrayentes. Como se ha 
descrito anteriormente, GPR55 se une a proteínas G12/13 y Gq, proteínas heterotriméricas implicadas en 
la invasión y metástasis de células tumorales. Utilizando dominantes negativos de estas proteínas G, 
hemos observado que GPR55 promueve la invasión vía Gq y que la activación de MMPs y el aumento 
de expresión de genes inductores de metástasis están también implicados en el efecto pro-invasivos 
inducido por GPR55. Por último, nuestros resultados muestran que GPR55 promueve el crecimiento 
tumoral y la colonización pulmonar in vivo. 
En conjunto, estos resultados apoyan que la implicación de GPR55 en el último y más letal paso en 
la progresión tumoral, y sugieren que su bloqueo farmacológico podría ser una nueva estrategia para el 
tratamiento del cáncer metastático. 
Como se ha descrito anteriormente, publicaciones recientes demuestran que GPR55 puede ser ac-
tivado por diferentes compuestos cannabinoides. Es bien conocido que los cannabinoides controlan la 
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proliferación celular. En células tumorales estos compuestos generalmente inducen un efecto bifásico: a 
bajas concentraciones estimulan la proliferación celular mientras que a altas concentraciones producen 
efecto anti-proliferativo. En este contexto, en el CUARTO CAPÍTULO de la Tesis hemos estudiado si 
GPR55 media el efecto del THC sobre la proliferación de células tumorales. Primero hemos analizado si 
la modulación de la expresión de GPR55 altera la respuesta al THC, y a continuación hemos intentado 
revelar cómo se controlan molecularmente estas respuestas. En concreto hemos estudiado si el THC 
induce liberación de calcio intracelular vía GPR55 y si el efecto del THC es producido por interacción de 
GPR55 con receptores de cannabinoides clásicos. Nuestros resultados demuestran que GPR55 media 
el efecto pro-proliferativo inducido por concentraciones bajas de THC. Así, el silenciamiento de GPR55 
en células de glioblastoma y de adenocarcinoma de mama bloquea el pico proliferativo inducido por 
THC, mientras que la sobreexpresión del receptor incrementa la proliferación celular. Además, nues-
tros datos demuestran la existencia de una interacción funcional entre GPR55 y CB1, y sugieren que 
distintos estados de interacción GPR55 /CB1 podrían ser la causa del efecto bifásico del THC sobre la 
proliferación de células tumorales.
En resumen, las CONCLUSIONES de esta Tesis son:
1. El receptor huérfano GPR55 proporciona ventajas pro-oncogénicas a las células tumorales, in-
duciendo su proliferación, migración e invasión tanto in vitro como in vivo. En consecuencia, niveles 
elevados de GPR55 en tumores humanos se correlacionan con una mayor agresividad tumoral y un 
peor pronóstico de los pacientes. 
2. GPR55 participa en el efecto del THC sobre la proliferación de células tumorales, concretamente 
en el aumento de la proliferación inducido por bajas concentraciones del cannabinoide.
En conjunto, nuestros datos sugieren que GPR55 podría ser una nueva herramienta con valor pro-
nóstico y una nueva diana terapéutica en cáncer.
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SUMMARY
G protein-couple receptors (GPCRs) constitute the largest superfamily of cellular receptors. They 
control crucial physiological functions and, consequently, their dysfunction contributes to many human 
diseases including cancer. In fact, they are -together with enzymes- the most common target of thera-
peutic drugs.
GPCRs are integral membrane proteins, characterized by an extracellular N-terminal domain, 7 trans-
membrane α-helices (7-TM) connected by 3 extracellular loops (ECL1, ECL2 and ECL3) and 3 intrace-
llular loops (ICL1, ICL2 and ICL3), ending in an intracellular C-terminal domain. They transform external 
stimuli (photons, neurotransmitters, chemokines, lipid mediators, hormones) into intracellular signals 
that will eventually trigger biological responses. 
Cancer is one of the most common diseases worldwide and one of the firsts causes of death in de-
veloped countries. Its incidence has grown in the past decades, and studies from the World Health Or-
ganization point to a continuous increase over the world in the coming years. Cancer is an evolutionary 
process that involves dynamic changes in the genome that result in accumulation of somatic mutations. 
During this process, normal cells acquire different capabilities that lead to malignant transformation. 
These capabilities are known as the “hallmarks of cancer”. Different studies have shown that GPCRs 
can modulate most, if not all, these hallmarks. Thus, GPCRs participate in favoring uncontrolled cell pro-
liferation, resistance to apoptosis, sustained angiogenesis, enhanceed tissue invasion and metastasis, 
and control tumor microenvironment. 
The wide spectrum of action of GPCRs in cancer physiopathology makes them potential anti-tumoral 
targets. However only few GPCRs are currently being therapeutically exploited in oncology. Understan-
ding the mechanism of action of GPCRs in cancer initiation and progression is therefore crucial to in-
crease the therapeutic armamentarium based on these receptors.  Orphan GPCRs, with no endogenous 
ligand assigned yet and whose physiological functions are in most cases unknown, constitute a very 
attractive population for such studies. GPR55 is an orphan GPCR that was first identified and cloned in 
1999. Several reports suggest that L-α-lysophosphatidylinositol (LPI) is the potential endogenous ligand 
for GPR55, and that different cannabinoid compounds can bind to and activate this receptor. GPR55 is 
widely express throughout the body, and, although little is still known about the physiological relevance 
and mechanism of action of the receptor, it has been proposed to regulate different physiological res-
ponses in the central nervous system, bone, immune system and vasculature, among others. 
Different indirect evidences suggest that GPR55 may be involved in cancer physiopathology. First, 
increased levels of LPI, the putative GPR55 endogenous ligand, have been found in plasma and asci-
tes from patients with ovarian cancer compared with women without oncogenic pathologies. Second, 
GPR55 couples to G12/13 and Gq, which are known to have oncogenic properties, and signals through 
Rho GTPases which control cytoskeleton organization, cell polarity and cell migration, all of them inti-
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matelly related to tumor progression. Finally, certain cannabinoids (compounds with known antitumoral 
actions) can activate GPR55.
In this context, the working HYPOTHESIS of this Thesis is that GPR55 participates in the control of 
tumor physio-pathology. In this context, the specific AIMS of this project are:
1. To study the expression of GPR55 in human tumors.
2. To investigate the role of GPR55 in tumor generation and progression.
3. To analyse whether GPR55 is involved in the effect of cannabinoids on cancer cell proliferation.
The RESULTS obtained in this Thesis are divided in four chapters.
In the FIRST CHAPTER we tried to determine whether GPR55 plays any significant role in cancer 
physiopathology. First, we analyzed the expression of GPR55 in a collection of human tumor cell lines 
and human breast cancer, glioblastoma and pancreatic adenocarcinoma samples. In addition, we mo-
dulated GPR55 expression in cancer cell lines (by transfection with HA-GPR55 constructions or genetic 
knock-down with specific siRNAs) to determine the involvement of GPR55 in cancer cell proliferation 
both in vitro and in vivo. We also characterized the molecular mechanisms underlying GPR55 action on 
cancer cells. We described that GPR55 is expressed in a wide variety of human cancers. In particular, 
we found that the expression of the receptor was significantly increased in tumoral tissues as compared 
with healthy tissues, and in highly aggressive vs poorly aggressive tumors. Moreover, GPR55 promotes 
cancer cell proliferation both in cell cultures and in xenografted mice through the overactivation of the 
extracellular signal-regulated kinase (ERK)/MAPK cascade. 
These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute 
a new biomarker and therapeutic target in oncology. 
In the SECOND CHAPTER, we studied in more detail the role of GPR55 in tumor generation and 
progression. To achieve this goal, we used the well-established model of chemically-induced skin carci-
nogenesis in mice lacking GPR55 and their corresponding wild-type littermates. We studied the effects 
of deleting GPR55 on malignant transformation, and we tried to unravel the molecular bases underlying 
such effects. Finally, we analyzed the expression of GPR55 in different human squamous cell carcino-
mas and we tried to determine whether this expression correlates with markers with clinical relevance. 
We demonstrated that GPR55 drives mouse skin tumor development. Thus, GPR55-deficient mice were 
more resistant to DMBA/TPA-induced papillomas, as indicated by a reduced generation of papillomas 
per animal than their corresponding wild-type littermates, and a decreased percentage of papilloma-car-
cinoma conversion. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advan-
tage on cancer cells, via overactivation of the ERK/c-Fos/cyclin D1 cascade. Our data also shows that 
6
GPR55 confers other oncogenic advantages on skin cancer cells. Thus, GPR55 enhances cancer cell 
anchorage-independent growth, invasiveness and tumorigenicity in vivo, suggesting that it not only pro-
motes tumor development but also enhances tumor aggressiveness.  Finally, we observed that GPR55 
is upregulated in human skin tumors and other human squamous cell carcinomas compared with the 
corresponding healthy tissues. 
Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and 
suggest that this receptor may be used as a new biomarker and therapeutic target also in squamous 
cell carcinomas.
In the THIRD CHAPTER of this Thesis, we investigated whether GPR55 participates in the metastatic 
process. Thus, we analyzed the effect of GPR55 on breast cancer cell migration and invasion in vitro and 
in tumor growth and lung colonization in vivo. For these studies we used breast cancer cells with stably 
knocked-down GPR55 levels or transfected with the corresponding control. We studied the downstream 
mechanisms responsible for the effects of GPR55 on the pro-metastasis-related features. Our results 
show that GPR55 induces the migration and invasion of the highly metastatic breast cancer cell line 
MDA-MB-231. This cell line expresses high levels of GPR55, and receptor donwregulation reduces the 
invasiveness of these cancer cells toward FBS and LPI, the proposed endogenous ligand of GPR55. 
Moreover, when GPR55 expression was reconstituted, tumor cells increased their invasion towards 
both chemoatracttants. As described before, GPR55 couples to G12/13 and Gq proteins, heterotrimeric 
G proteins that have been implicated in tumor invasion and metastasis. By using negative dominants 
of the G proteins, we demonstrated that GPR55 drives breast cancer cell invasion via Gq signaling, and 
our results suggest that activation of MMPs and the upregulation of metastasis-inducing genes are also 
involved in the effect of GPR55 on cancer cell invasion and migration. Finally, our data show that GPR55 
promotes breast cancer tumor growth and lung colonization in vivo. 
Together, these results support the involvement of GPR55 on the latest and most lethal stage of 
cancer progression, and suggest that its pharmacological blockade could be a new strategy to manage 
metastatic cancer.
Recent reports have shown that GPR55 can be activated by different cannabinoid compounds. In 
addition, it is well established that cannabinoids control cell proliferation. These compounds generally 
induce a biphasic effect: while low concentrations induce cancer cell proliferation, high concentrations 
exert their well-known anti-proliferative action. Thus, in the FOURTH CHAPTER we studied whether 
GPR55 mediates the effects of THC on cancer cell proliferation. First, we analyzed the consequence 
of modulating GPR55 expression on THC action. Then, we tried to unravel how THC produces such 
effects via GPR55. In particular, we studied whether THC promotes a release of intracellular calcium via 
GPR55 and whether THC action is produced by functional interaction of GPR55 with classical cannabi-
noid receptors. We show that GPR55 mediates cancer cell proliferation induced by low concentrations 
of THC. Thus, knocked-down of GPR55 in glioblastoma and breast adenocarcinoma cells blocked the 
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pro-proliferative effect induced by THC, while overexpression of the receptor enhanced proliferation. 
Moreover, our data show that there is a functional interaction between GPR55 and CB1 cannabinoid 
receptors, and suggests that the interaction status of these receptors may underlie the biphasic effects 
of THC on cell proliferation. 
In summary, the CONCLUSIONS of this Thesis are:
1- The orphan receptor GPR55 confers pro-oncogenic advantages on tumor cells in vitro and in 
mouse cancer models by promoting their proliferation, migration and invasion. Consequently, elevated 
expression of GPR55 in human tumors is associated to high aggressiveness and poor prognosis.
2- GPR55 participates in the proliferative effect of THC on cancer cells as produced by low concen-
trations of the cannabinoid. 
Together, these conclusions point to GPR55 as a new biomarker, with possible prognostic value, and 
as a new therapeutic target in oncology. 
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1. G protein-coupled receptors 
In a biological system, the interaction between 
the external environment and the inside is crucial. 
In cells, this important role is mostly mediated by 
proteins present in their membranes. G protein-
coupled receptors (GPCRs) constitute the largest 
superfamily of such proteins, with more than 800 
members in the human genome. They transform 
external stimuli (photons, neurotransmitters, che-
mokines, lipid mediators, hormones) into intrace-
llular signals that will eventually trigger biological 
responses. These responses modulate a wide 
range of physiological functions such as vision, 
neurotransmission, cell proliferation, blood pres-
sure, olfaction and taste (Pierce et al., 2002; Ro-
senbaum et al., 2009). 
GPCR structure
GPCRs have been known for more than 40 
years (Hill, 2009). The first 3D structure correspon-
ding to a GPCR-related protein, the proton pump 
bacteriorhodopsin, was solved in 1975 from Ha-
lobacterium halobium using electron microscopy 
(Henderson and Unwin, 1975). However, it wasn’t 
until 2000 when the first X-ray high-resolution 
structure of a GPCR was determined, in this case, 
of the inactive visual receptor rhodopsin (Palc-
zewski et al., 2000). Another 7 years where nee-
ded to solve the structure of a GPCR bound to 
a ligand, the β2-adrenergic receptor bound to its 
antagonist calazolol (Cherezov et al., 2007; Ras-
mussen et al., 2007; Rosenbaum et al., 2007).
GPCRs are integral membrane proteins, cha-
racterized by an extracellular N-terminal domain, 
Figure 1. GPCR structure. GPRCs are integral proteins formed by an extracellular N-terminal domain, 7 transmembrane 
α-helices (7TM) concerted by 3 extracellular loops (ECLS) and 3 intracellular loops (ICL), ending in an intracellular C-
terminal. GPCRs can be activated by a wide variety of stimuli. These ligands are recognized mainly by the ECLs, interact 
with the TM domains (in the so called binding pocket), activate the receptor producing a conformational change that 
allows it to interact with downstream effectors (mainly, but not only, heterotrimeric G proteins).
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7 transmembrane α-helices (7-TM) connected by 
3 extracellular loops (ECL1, ECL2 and ECL3) and 
3 intracellular loops (ICL1, ICL2 and ICL3), ending 
in an intracellular C-terminal domain (figure 1)
(Audet and Bouvier, 2012; Venkatakrishnan et al., 
2013). They can be grouped into five major clas-
ses on the basis of their sequence and structural 
similarity: rhodopsin-like (class A), secretin-like 
(class B), metabotropic glutamate-like (class C), 
adhesion and Frizzled/Taste2 (figure 2) (Audet and 
Bouvier, 2012; Rosenbaum et al., 2009). Most of 
the GPCRs belong to the classes A, B and C, be-
ing the rhodopsin-like family the largest and most 
diverse, with conserved sequence motifs that im-
ply shared structural features and activation me-
chanisms.
The principal structure studies have been 
made in the class A receptors. The members of 
this class differ in their extracellular loops and 
ligand-binding regions while the folding of the 
TM domains is highly conserved. The extracellu-
lar loops, mainly ECL2, are responsible for ligand 
recognition and access into the binding pocket in 
the TM region (Venkatakrishnan et al., 2013). The 
TM region is the structural core of the receptor 
where ligands bind (“ligand-binding pocket”) and 
is in charge of transducing the information to the 
intracellular region. TM3 is essential for GPCR 
structure and function, and presents consensus 
contacts with TM2, TM4, TM5 and TM6. TM3 has 
a conserved motif (E/DRY motif) that regulates 
GPCR conformational state. The triplet of amino 
acids that constitute this motif (Glu/Asp-Arg-Tyr) 
form a network of polar interactions with amino 
acids in TM6 creating an “ionic lock” that stabi-
lizes the inactive-state of the receptor. When li-
gands access the binding pocket, they interact 
with residues from TM3, TM6 and TM7, occupying 
similar spaces. The variation on the amino acids 
in these regions provides ligand specificity (Au-
det and Bouvier, 2012; Millar and Newton, 2009). 
Ligand binding produces a conformational chan-
ge in the TM core that leads to the disruption of 
the interactions in the “ionic lock” and the subse-
quent rearrangement of TM6 and the associated 
intracellular loop. This movement allows the inte-
raction of ICL2 with the E/DRY motif in TM3, fa-
voring receptor stability and generating a pocket 
for interaction with heterotrimeric G proteins and 
other intracellular effectors (Audet and Bouvier, 
2012; Millar and Newton, 2009; Rosenbaum et 
al., 2009; Venkatakrishnan et al., 2013). Peptide 
motifs present in ICL3 and the C-terminal domain 
determine the specific partner that will interact 
with each GPCR. The C-terminal region also con-
tains sequences susceptible of post-translational 
modification (phosphorylation associated to des-
ensitation, palmitoylation for lipid raft recognition, 
etc.) (Venkatakrishnan et al., 2013) (figure 1). 
It has been classically accepted that GPCR ac-
tivation occurs according to the two-state model. 
GPR55%
Figure 2. GPCR network. Classification of GPCRs in the 
five major classes: Rhodopsin, adhesion, secretin, gluta-
mate and Frizzled/Tas2. The GPCR studied in this Thesis, 
GPR55, is highlighted.
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In this model, the receptor presents two confor-
mations, the inactive (R) state, that has low affinity 
for agonists, versus the active (R*) state that binds 
agonists with high affinity and couples to G pro-
teins activating downstream signaling pathways. 
The receptor exists in an equilibrium between the-
se two states, and agonist binding displaces the 
equilibrium to the R* state (Gether and Kobilka, 
1998; Park et al., 2007). Emerging evidences po-
int to a highly dynamic and more complex scena-
rio where the receptor could be in different con-
formational states (not only R and R*), that would 
lead to the modulation of different intracellular 
signaling pathways (Park, 2012; Venkatakrishnan 
et al., 2013). 
It was generally admitted that GPCRs function 
as monomers, but accumulating evidence su-
pport that GPCRs, like other cell surface recep-
tors, can form dimers or oligomers. Indeed, bio-
chemical, biophysical and functional analyses 
demonstrate that GPCRs are expressed in the 
cell surface as oligomers (Audigier et al., 2013; 
Pierce et al., 2002; Vischer et al., 2011). These re-
ceptor interactions have profound consequences 
on cell signaling. For example, heterodimerization 
is required in some cases to produce the activa-
tion of particular effects [dimerization of GABAB1 
and GABAB2 receptors for receptor signaling (Pin 
et al., 2004); dimerization of taste receptors T1R3 
with T1R1 or T1R2 for umami and sweet sensa-
tions, respectively (Zhao et al., 2003); dimerization 
of β2-adrenergic with α1D-adrenergic receptors for 
receptor cell surface targeting (Uberti et al., 2005), 
etc.]. In other cases, receptor heterodimerization 
modulates the functional features of the individual 
monomers. For example, activation of mGlu2 in 
heteromers with 5-HT2A increases the affinity of 
this latter receptor for its ligand (Gonzalez-Maeso 
et al., 2008). Another example are D1-D2 dopami-
ne receptor heteromers, which couple to Gq while 
D1 and D2 in their monomeric forms signal through 
Gs and Gi proteins, respectively (Lee et al., 2004; 
Rashid et al., 2007). 
GPCR signaling pathways
The canonic GPCR-activated signaling pa-
thway relies on the activation of heterotrimeric G 
proteins, although they can also signal via non-G 
proteins.
Heterotrimeric G protein pathway
Heterotrimeric G proteins, also called guanine 
nucleotide-binding proteins, are GTPases formed 
by three subunits (α, β and γ). In their inactive sta-
te, a GDP molecule is bound to the α subunit. The 
interaction of an activated GPCR with the G pro-
tein induces the exchange of GDP to GTP, thus 
acting the receptor as a GEF (guanine nucleotide 
exchange factor). This switch produces the disso-
ciation of the α subunit and the βγ dimers, leading 
to the subsequent modulation of different downs-
tream effectors (Kostenis et al., 2005; Oldham and 
Hamm, 2008). The GTP bound to the active Gα is 
hydrolyzed by the intrinsic GTPase activity of this 
subunit. This process is accelerated by GTPase-
activating proteins (GAPs). Gα-GDP re-associates 
with βγ dimers, re-assembling the heterotrimeric 
proteins and ending the G-protein activation cycle 
(Milligan and Kostenis, 2006)(figure 3).
G proteins are divided in four main classes 
based on amino acid identity of the Gα subunit: 
Gαs, Gαi/o, Gαq/11 and Gα12/13 (Milligan and Koste-
nis, 2006). Gαs activates adenylyl cyclase (AC), 
increasing the levels of 3’,5’-cyclic adenosine 
monophosphate (cAMP) and subsequently ac-
tivating protein kinase A (PKA), which regulates 
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many functions such as cell metabolism, cellular 
secretion and membrane permeability, among 
many others. On the contrary, Gαi/o inhibits AC, 
the production of cAMP and, for example, Ca2+ 
ion channels, leading to opposite effects. It has 
been shown that this pathway is particularly im-
portant in cell motility and regulation of neuronal 
transmission, for example. Gαq/11 stimulates phos-
pholipase C-β (PLCβ) that regulates the release 
of intracellular Ca2+ through the generation of IP3 
and DAG. This signaling participates in the control 
of the stimulation of mitogen-activated protein ki-
nases (MAPKs) and the regulation of proliferation 
and production of cytokines, for example. Gα12/13 
activates mainly the Rho GTPase signaling pa-
thway, which is important in cell proliferation, mi-
gration, regulation of cell-cell adhesion, and has 
been involved in many aspects of tumor progres-
sion (Marinissen and Gutkind, 2001; Milligan and 
Kostenis, 2006; Riobo and Manning, 2005; Wu et 
al., 2012)(figure 3). 
Initially, it was believed that the βγ dimer was 
just binding to the Gα subunit, anchoring the he-
terotrimer to the plasma membrane and inhibiting 
spontaneous signaling. Today, it is well known 
that the βγ dimers can interact with and activa-
te different effectors, such as ion channels, PLC 
and components of the MAPK cascades, produ-
cing specific functional responses (Cabrera-Vera, 
2003; Milligan and Kostenis, 2006). 
Non-G protein pathway
Although most GPCR-mediated effects are 
produced via signaling through heterotrimeric G 
proteins, it is currently admitted that GPCRs inte-
ract with many other proteins, collectively termed 
Figure 3. GPCR activation and signaling. GPCR activation by ligand binding induces the interaction of the receptor 
with heterotrimeric G proteins. Both α and βγ and dimers activate then different signaling pathways that modulate a 
wide variety of biological responses. GEF, guanine nucleotide exchange factor; GTP, guanosine triphosphate; GDP, 
guanosine diphosphate; GAP, GTPase-activating proteins; PI3K, phosphoinositide 3-kinase; PLC, phospholipase C; 
Cdc42, cell division control protein 42; AC, adenylate cylcase; cAMP, cyclic adenosine monophosphate; PKA, protein 
kinase A; PIP2,phosphatidylinosito 4,5-biphosphate; IP3, inositol-1,4,5-triphosphate; DAG, dyacilglycerol; CaMK, Ca2+/
calmodulin-dependent protein kinase; PKC, protein kinase C; RhoA, Ras homolog gene family member A.
16
GPCR-interacting proteins (GIPs). These interac-
tions either modulate GPCR signaling or function 
to couple these receptors to heterotrimeric G pro-
tein-independent signaling pathways. In addition, 
GPCRs interact with proteins that regulate their 
trafficking to different cellular compartments, en-
docytosis or processing in the endoplasmic reti-
culum among others (Maurice et al., 2011; Pierce 
et al., 2002). 
One of the most studied non-G protein signa-
ling pathways is the one mediated by β-arrestins. 
β-arrestins are endocytic adaptor proteins that 
facilitate the targeting of receptors to clathrin-
mediated endocytosis. They can bind to activa-
ted GPCRs that have been phosphorylated by G 
protein-coupled receptor kinases (GRKs) or se-
cond messenger protein kinases like PKA or PKC, 
thus directing the receptors to desensitation by 
endocytosis. β-arrestin binding is crucial for re-
ceptor desensitization and internalization. But 
β-arrestins can also act as adaptor proteins trig-
gering heterotrimeric G protein-independent sig-
naling. For example, β-arrestins can bind to the 
non-receptor tyrosine kinase Src family and can 
couple GPCRs to MAPK cascades [such as the 
extracellular signal-regulated kinase (ERK), p38 
or c-Jun N-terminal kinase 3 (JNK3)], or to the 
phosphatidylinositol 3-kinase (PI3K)/Akt signaling 
pathway, among others (Luttrell and Lefkowitz, 
2002; Maurice et al., 2011; Shukla et al., 2011). 
GPCRs and cancer
GPCRs control crucial physiological functions, 
and their deregulation contributes to many patho-
logies like asthma, inflammation, obesity, pain, 
cardiovascular and central nervous system disea-
ses and cancer. In fact, more than half of the the-
rapeutic agents used in the clinic target directly or 
indirectly GPCRs (Dorsam and Gutkind, 2007; Wu 
et al., 2012). 
Cancer is one of the most common diseases 
worldwide and one of the firsts causes of deaths 
in developed countries. Its incidence has grown 
in the past decades, and studies from the World 
Health Organization point to a continuous increa-
se over the world in the coming years. Cancer is 
an evolutionary process that involves dynamic 
changes in the genome that result in accumula-
tion of somatic mutations (Blanpain, 2013; Ha-
nahan and Weinberg, 2000). During this process, 
normal cells acquire different capabilities that 
lead to malignant transformation. These capa-
bilities are known as the “hallmarks of cancer”, 
and are defined by: 1) self sufficiency in growth 
signals, 2) insensitivity to anti-growth signals, 3) 
resistance to apoptosis, 4) sustained angiogene-
sis, 5) enhanced tissue invasion and metastasis 
capabilities and 6) limitless replicative potential 
(Hanahan and Weinberg, 2000; 2011).
Different studies have shown that GPCRs can 
modulate most, if not all, of these hallmarks (figu-
re 4). The first direct link between cancer and GP-
CRs was reported in 1986, where the overexpres-
sion of the oncogene MAS (that encodes a GPCR) 
promoted focus formation in vitro and tumorige-
nesis in vivo (Young et al., 1986). Since then, abe-
rrant GPCR signaling has been found in different 
cancers, favoring tumor development and pro-
gression (Li et al., 2005). This abnormal signaling 
is due either to aberrant overexpression of GP-
CRs (such as endothelin receptors, chemokine 
receptors, lysophosphatidic acid (LPA) receptors 
and sphingosine 1-phosphate (S1P) receptors), 
or to mutations in key residues that constitutively 
activate the receptor or by aberrant activation by 
their agonists, released by either tumor or stromal 
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cells (Dorsam and Gutkind, 2007; Li et al., 2005; 
O’Hayre et al., 2013). 
GPCRs and uncontrolled cell proliferation
Normal cells have an extremely accurate ma-
chinery that controls their proliferation. They only 
divide in response to growth signals that bind to 
specific membrane receptors, activating diffe-
rent intracellular signaling cascades that promote 
cell cycle progression and proliferation. If these 
signals are not present, proliferation is inhibited. 
This tight control is crucial for the regulation of tis-
sue homeostasis, structure and function. Cancer 
cells, by generating their own growth signals, can 
bypass these controls, which results in the persis-
tent stimulation of their receptors and the conse-
quent uncontrolled cell proliferation (Hanahan and 
Weinberg, 2000; 2011). Many potent mitogens 
such as thrombin, LPA, gastrin-releasing peptide 
(GRP), endothelin and prostaglandins stimulate 
cell proliferation by activating their specific GP-
CRs. Some of these receptors are overexpressed 
in cancer cells, promoting uncontrolled cell proli-
feration (Dorsam and Gutkind, 2007; Marinissen 
and Gutkind, 2001). This is the case, for example, 
of protease-activated receptor (PAR). When this 
receptor is activated by serine proteases such 
as thrombin, it couples to Gi, Gq and G12/13 pro-
teins, leading to the activation of diverse signa-
ling pathways, including the pro-survival PI3K/
Akt axis, MAPK cascades, Rho kinase and PLC, 
that promote cell survival, proliferation, migra-
tion and adhesion (Coughlin, 2000; Zigler et al., 
2011). Another example of GPCRs overexpressed 
in cancer are the endothelin receptors (ETA and 
ETB). The vasocontrictive peptide endothelin, by 
binding to its specific receptor, stimulates the 
ERK/MAPK cascade, an important regulator of 
cell proliferation (Bagnato et al., 2011). Aberrant 
signaling mediated by overexpression of these 
receptors has been implicated in melanoma and 
Figure 4. Role of GPCRs in cancer development. GPCRs promote cancer cell proliferation (1) and evasion 
of apoptosis (2), leading to tumor growth. They also promote sustained angiogenesis (3), enhance invasion and 
metastatic capabilities (4), and help tumor cells to create an advantageous tumor microenvironment that favors 
tumor progression (5). 
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prostate cancer progression. Moreover, many pa-
tients with metastatic cancer present elevated le-
vels of endothelin in plasma, which contributes to 
the overactivation of the system and the conse-
quent worsening prognosis (Dorsam and Gutkind, 
2007). LPA receptors are also overexpressed in 
many human tumors including lung, breast, sto-
mach, ovary, kidney and prostate cancers (Mur-
ph, 2008; Panupinthu et al., 2010). LPA binds to 6 
different LPA receptors [LPA(1-6)] that are coupled 
to Gi, Gq and G12/13 proteins, activating multiple 
oncogenic signaling pathways. In addition, eleva-
ted expression of autotaxin (the phospholipase D 
that produces LPA from lysophosphatidylcholine) 
and LPA are found in the plasma of certain cancer 
patients, increasing the aberrant signaling initia-
ted by LPA (Panupinthu et al., 2010) (Box 1).
Interestingly, many orphan GPCRs are emer-
ging as important molecular players in cancer, 
even though no specific ligand has been assigned 
to them yet. One example is GPR19. Overexpres-
sion of this receptor accelerates cell-cycle pro-
gression, conferring a proliferative advantage on 
lung cancer cells. This effect was associated with 
the modulation of cyclin B1 levels and the transi-
tion from G2 to mitosis in the cell cycle (Kastner 
et al., 2012).
GPCRs and resistance to apoptosis
When a normal cell detects genotoxic dama-
ge, antiproliferative or death-inducing signals or 
uncontrolled cell proliferation, it turns on anti-
proliferative signaling pathways and/or the death 
machinery. Cancer cells present the ability to eva-
de these death signals, leading to cancer cell sur-
vival and the growth of tumors. Aberrant GPCR 
signaling has been implicated in this process. For 
example, S1P, by binding to its specific GPCRs, 
increases the expression of the anti-apoptotic 
protein BCL-2 (Sauer et al., 2005), inactivates the 
pro-apoptotic protein BAD and impairs caspase 
activation by blocking the translocation of BAX 
to the mitochondria (Betito and Cuvillier, 2006), 
thereby protecting the cells against apoptosis. 
Regarding orphan GPCRs, constitutive activation 
of GPR18, which is highly overexpressed in mela-
nomas, is able to inhibit apoptosis by promoting 
cancer cell survival (Qin et al., 2011).
GPCRs and sustained angiogenesis
Once tumors reach a certain size in their pri-
mary site, they demand extra nutrients and oxy-
gen supply that cannot be supported by the nor-
mal tissue vasculature. At this point, the tumors 
use different strategies to generate a new vascu-
lar network that will cover these highly deman-
ding metabolic needs. The new blood vessels 
also provide a route of dissemination for cancer 
cells through the systemic circulation, allowing 
them to reach distant sites where they can ge-
nerate new tumoral masses known as metastasis 
(Hanahan and Weinberg, 2000; 2011). To induce 
angioneogenesis, tumor cells promote survival, 
proliferation, migration and tube alignment of en-
dothelial cells. The vascular endothelial growth 
factor (VEGF) is one of the main pro-angiogenic 
signals and it is upregulated in many tumors (Ri-
chard et al., 2001). Increased levels of VEGF of-
ten rely on thrombin overexpression. This serine 
protease activates PAR (GPCR) receptors, which 
stimulates the secretion of VEGF, increasing vas-
cular permeability and inducing the production 
of matrix metalloproteinases (MMPs). These en-
zymes degrade the extracellular matrix, favoring 
the migration and proliferation of endothelial cells, 
and subsequent vessel formation (Richard et al., 
2001; Yin et al., 2003). In addition, PAR-1 activa-
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tion induces the secretion of the angiogenic che-
mokines interleukin (IL)-8 and growth-regulated 
oncogene-α (GRO-α). These chemokines activate 
the chemokine receptors CXCR1 and CXCR2 on 
endothelial cells, inducing their proliferation, tube 
formation and migration, thus promoting angio-
genesis (Agarwal et al., 2010). The chemokine 
CXCL12, by binding to and activating its speci-
fic GPCR (CXCR4), induces angiogenic respon-
ses as well in human basal cell carcinoma, breast 
cancer, pancreatic cancer and laryngeal and 
hypopharyngeal squamous cell carcinoma. Thus, 
tumors that express high levels of CXCR4 present 
higher blood vessel density as a consequence of 
Box 1. Lysophospholipids and cancer. Lipids are the main component of cell membranes and es-
sential sources of energy, but some of them are also important signaling mediators. Thus, they regulate 
cardiovascular functions, immune responses and brain development, just to name a few. Lysophospholi-
pids are probably the best characterized signaling bioactive lipids, LPA (lysophosphatidic acid) and S1P 
(sphingosine 1-phsophato) being the most representative. They exert growth factor-like effects such as 
induction of proliferation, survival, migration, adhesion and differentiation (Mutoh and Chun, 2008). Both 
LPA and S1P mediate most of their biological functions by binding to and activating specific GPCRs. So 
far, 6 receptors have been identified for LPA (LPA1-3, that belong to the endothelial differentiation gene (Edg) 
family and LPA4-6, related to the purinergic receptor family) and 5 for S1P (S1P1-5), but additional putative 
lysophospholipid receptors have been proposed in the literature (Mutoh et al., 2011).
Lysophopholipid metabolism and receptor activation are tightly regulated under normal physiological 
conditions. Their deregulation can lead or contribute to different pathologies, including cancer.  Thus, as-
citic fluid and plasma from patients with ovarian cancer present increased levels of LPA (Sutphen et al., 
2004a; Xiao et al., 2001; Xu et al., 1995; 1998) and S1P (Hong et al., 1999). LPA is also increased in the 
plasma of hepatocellular carcinoma patients (Skill et al., 2012) and the levels of S1P in serum from stage IIIA 
human breast cancer patients is higher than that of healthy volunteers (Nagahashi et al., 2012). Moreover, 
LPA and S1P receptors are aberrantly expressed in tumors from different origins. Thus, LPA2 and LPA3 
receptors are upregulated in ovarian (Fang et al., 2002), colon (Shida et al., 2004), thyroid (Schulte et al., 
2001), breast (Kitayama et al., 2003), gastric (Yamashita et al., 2005a) and prostate (Im et al., 2000; Zeng et 
al., 2009) cancers. In addition, high expression of S1P receptors has been detected in thyroid (Balthasar et 
al., 2006), gastric (Yamashita et al., 2005b) and breast (Pyne, 2012) cancers. As well, the enzymes in charge 
of the synthesis of LPA and S1P are aberrantly expressed in tumors. LPA is produced extracellularly from 
lysophosphatidylcholine by autotaxin (ATX), a lysophospholipase D. ATX is overexpressed in tumors from 
different origins, such as breast cancer, glioblastoma, thyroid carcinoma, non-small cell lung cancer and 
hepatocellular carcinoma among others. Moreover, overexpression of ATX increases tumor growth, tumor 
aggressiveness and angiogenesis (Houben and Moolenaar, 2011; Murph and Mills, 2007). S1P is produced 
by sphingosine kinases (SKs) by catalizing the phosphorylation of sphingosine. The fact that SK1 overex-
pression induced the transformation of NIH3T3 fibroblasts, increasing cell growth and tumor development 
in immunodeficient mice, was one of the first evidences of the potential oncogenic role of SK1 (Xia et al., 
2000). In addition, the expression of SK1 is elevated in many cancers such as breast, stomach, lung, colon 
or brain among others, and its expression corralates with increased tumor grade and reduce patient survi-
val (Murph and Mills, 2007; Pyne and Pyne, 2010). 
Both LPA and S1P receptor stimulation activates oncogenic pathways via Gαi, Gα12/13 and Gαq, pro-
moting cell survival, cell proliferation, cytoskeletal remodeling, cell migration and invasion among others, 
which in turn promotes tumor initiation and progression (Houben and Moolenaar, 2011; Pyne and Pyne, 
2010).
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an enhanced secretion of angiogenic factors such 
as VEGF, IL-8 and IL-6 by tumor cells (Chu et al., 
2009; Li et al., 2012; Liang et al., 2007; Matsuo et 
al., 2009).
Lysophospholipids and their GPCRs are also 
important mediators of angiogenesis. Both LPA 
and S1P are associated with endothelial cell pro-
liferation, migration and survival (Morris et al., 
2009). In line with this notion, the expression of 
S1P1 receptors is enhanced in tumor vessels and 
their knocked-down in vivo suppresses tumor 
growth by inhibiting the stabilization of new blood 
vessels (Chae et al., 2004). Overexpression of 
LPA1 and LPA3 receptors in neuroblastoma cells 
enhanced the expression of Vegf-A, resulting in 
increased endothelial cells motility and angio-
genesis promotion. A similar effect is produced 
by an active mutated form of LPA1 (Kitayoshi et 
al., 2012). Of interest, the VEGF produced via 
activation of LPA receptors generates a positive 
feedback loop by inducing autotaxin (enzyme in 
charge of LPA generation) and LPA1 expression 
(Ptaszynska et al., 2010).
GPCRs and enhanced tissue invasion and me-
tastasic capabilities
The final stage in cancer is metastasis. Metas-
tasis causes a significant reduction in patients’ 
quality of life and is responsible for most can-
cer-related deaths. This process consists in the 
spreading of cancer cells from primary tumors to 
distant locations, and it is produced in four steps: 
i) cancer cells scape from the primary tumor and 
enter the blood or lymphatic vessels (intravasa-
tion); ii) these cancer cells have to survive in the 
circulation until they reach a new organ to colo-
nize; iii) cancer cells leave the circulatory system 
(extravasation) and iv) they colonize the distant 
niche and generate a new tumor (Nguyen et al., 
2009). 
An important step in metastasis is degrada-
tion of the extracellular matrix, so the tumor cells 
can spread. This function is mediated in part by 
matrix metalloproteinases (MMPs) that promote 
cell invasion and motility. Expression and activi-
ty of MMP-2 and MMP-9 are frequently elevated 
in human cancer, which correlates with increa-
sed metastasis and poor prognosis (Hua et al., 
2011). MMPs are regulated by activator protein-1 
(AP1)-dependent transcription (Sato et al., 1993), 
a nuclear response that is elicit by most GPCRs 
(Dorsam and Gutkind, 2007). For example, S1P 
by activating S1P3 receptors via ERK, p38 and Akt 
induces the expression and activation of MMP-9, 
which favors an invasion and migration phenoty-
pe (Kim et al., 2011).
In addition, activation of G12/13 proteins by GP-
CRs has been associated to tumor migration and 
invasion. These G proteins activate effectors, such 
as Rho GTPases and cadherins among others, 
effectors that are essential in the control of cell-
cell adhesion, organization of the actin cytoes-
queleton, microtubules dynamics, etc., which in 
turn regulate cell invasion and metastasis (Kelly 
et al., 2007).
Certain types of cancers preferentially me-
tastasize to specific organs. For example, most 
breast cancers generate metastases in the bones, 
lungs, brain and liver (Nguyen et al., 2009). Se-
lectivity towards a specific organ is determined 
by different factors, including mechanical and 
anatomical considerations that will facilitate the 
settlement of the tumor cells in specific locations. 
This selectivity is also driven by factors that are 
expressed at the site of metastasis, either by tu-
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mor cells or by stromal cells, and by intrinsic pro-
perties of the tumor cells themselves due to diffe-
rential gene profiles (Ben-Baruch, 2007; Nguyen 
et al., 2009). It has been described that one of the 
main responsibles for organ-specific metastasis 
are chemokines and their GPCRs. Chemokines 
are released at the distant organs and the expres-
sion of their receptors by tumor cells directs their 
migration to these specific sites, regulating their 
adhesion and invasion capabilities (Ben-Baruch, 
2007). Many breast tumors overexpress the che-
mokine receptor CXCR4, providing proliferative, 
pro-survival and pro-migratory advantages to 
cancer cells. The organs that are most frequently 
colonized by these cells are lymph nodes, lungs, 
bone marrow and liver. Interestingly, these or-
gans express high levels of the CXCR4 endoge-
nous ligand, the chemokine CXCL12, attracting 
the tumor cells to these sites (Dorsam and Gut-
kind, 2007; Fernandis et al., 2004; Hembruff and 
Cheng, 2009; Müller et al., 2001). Moreover, under 
hypoxia conditions, a factor of poor prognosis, 
the hypoxia-inducible factor-1 (HIF-1), is stabili-
zed, activating genes that promote angiogenesis, 
anaerobic metabolism, cell survival and invasion 
(Harris, 2002). In different tumor cell lines, inclu-
ding breast cancer cells (Shim et al., 2006), glio-
blastoma cells (Zagzag et al., 2006), renal cell 
carcinomas (Staller et al., 2003), chondrosarcoma 
cells (Sun et al., 2010),  oral squamous cell carci-
nomas (Ishikawa et al., 2009) and ileal carcinoid 
cells (Arvidsson et al., 2010), one of the genes ac-
tivated by HIF-1 is CXCR4, which promotes cell 
invasion.  Another example of a GPCR directing 
the metastatic spreading to a specific site is the 
C-C chemokine receptor type 7 (CCR7). This re-
ceptor is overexpressed in many human cancer 
cells such as breast cancer cells (Cabioglu et al., 
2005; Müller et al., 2001), gastric cell carcinomas 
(Mashino et al., 2002), colorectal cell carcinomas 
(Günther et al., 2005), cervical cancer cells (Koda-
ma et al., 2006), esophageal squamous cell carci-
nomas (Ding et al., 2003) and non-small lung can-
cer cells (Koizumi et al., 2007), conferring them 
migration and invasion properties, and specifying 
their metastasis to the lymph nodes. In support of 
this idea, metastatic lymph nodes present high le-
vels of the CCR7 ligands (the chemokines CCL21 
and CCL19) compared to healthy nodes (Müller et 
al., 2001; Wilson et al., 2006).
GPCRs and tumor microenvironment
Growing evidence indicates that the tumor mi-
croenvironment, made up of stromal and immune 
cells, plays a pivotal role in cancer progression. 
It was classically admitted that the immune cells 
present in tumors had the mission of eradicating 
the neoplastic lesion. However, emerging eviden-
ce suggest that these cells can also favor tumor 
formation and progression (Hanahan and Wein-
berg, 2011). Thus, many of the signals that in-
duce cancer cell proliferation, angiogenesis and 
metastasis come not only from tumor cells but 
also from the immune system and stromal cells. 
Moreover, both immune and stromal cells produ-
ce prostaglandins, cytokines and/or chemokines 
that activate their cognate GPCRs, thereby fa-
voring tumor progression (Dorsam and Gutkind, 
2007). For example, the increased expression of 
IL-8/CXCR2 specifically in the tumor microen-
vironment enhanced colon cancer growth and 
metastasis, while selective deletion of CXCR2 in-
hibited cancer growth and angiogenesis (Lee et 
al., 2012). In addition, fibroblasts and pancreatic 
cancer cells co-operate to induce neoangiogene-
sis, by promoting endothelial cell proliferation, mi-
gration and tube formation (Matsuo et al., 2009). 
Fibroblasts produce the chemokine CXCL12 that 
induces both the proliferation and migration of 
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endothelial cells, and the invasion of tumor cells 
through activation of its receptor CXCR4 in a pa-
racrine manner. Moreover, CXCL12 significantly 
enhanced the production in pancreatic carcinoma 
cells of IL-8, a chemokine that activates CXCR1 
and CXCR2 receptors on endothelial cells, poten-
tiating their proliferation, migration and tube for-
mation (Matsuo et al., 2009). But the cooperation 
between fibroblasts and cancer cells is bidirec-
tional as suggested by the fact that the produc-
tion of CXCL12 in fibroblasts was increased by 
the co-culture with tumor cells. Together, these 
results indicate that the interaction between tu-
mor and stroma cells promote tumor angiogene-
sis and metastasis by regulating the production of 
chemokines (Matsuo et al., 2009). 
An emerging important component of tumor 
microenvironment are “CAFs”, named after can-
cer-activated fibroblasts, which are characteri-
zed by the expression of α-smooth muscle actin 
(α-SMA) and by the production of extracellular 
matrix proteins. Normal stroma in most organs 
contains minimal number of fibroblasts, while 
tumor stroma has an increased number of the-
se cells (Kalluri and Zeisberg, 2006). CAFs from 
human breast carcinomas secrete high levels of 
CXCL12, that by activating CXCR4 receptors, 
promote the growth of breast carcinoma cells. 
Additionally, CXCL12 mediates the chemotaxis 
and recruitment of endothelial progenitor cells 
into the carcinoma, inducing angiogenesis (Orimo 
et al., 2005).
Tumor-associated macrophages interact with 
tumor cells as well, promoting tumorigenesis 
and metastasis (Hao et al., 2012). Some GPCRs 
play essential roles in this interaction. For exam-
ple, macrophages that express the endothelin 
receptor ETB are directed towards hypoxic tu-
mor areas, which express elevated levels of en-
dothelins (Grimshaw et al., 2002). As a validation 
of this observation, selective knock-down of the 
ETB receptor in the stroma reduced the number of 
infiltrating macrophages and, as a consequence, 
diminished breast cancer tumor growth and me-
tastasis (Binder et al., 2009).
2. GPR55
The wide spectrum of action of GPCRs in can-
cer physiopathology makes them potential anti-
tumoral targets. However, only few a GPCRs are 
currently being therapeutically exploited in on-
cology. Understanding the mechanism of action 
of GPCRs in cancer initiation and progression is 
therefore crucial to increase the therapeutic ar-
mamentarium based on these receptors.  Orphan 
GPCRs, with no endogenous ligand assigned yet 
and whose physiological functions are in most ca-
ses unknown, constitute a very attractive popula-
tion for such studies. 
The orphan receptor GPR55 was first identi-
fied and cloned in 1999 (Sawzdargo et al., 1999). 
GPR55 belongs to the rhodopsin-like family of 
GPCRs, and its amino acid sequence share sig-
nificant identities with the LPA recptors. Thus, 
GPR55 has 30% sequence identity with LPA5 and 
LPA4, and 29% with LPA6 (Elbegdorj et al., 2013; 
Sawzdargo et al., 1999).
GPR55 pharmacology
According to the International Union of Basic 
and Clinical Pharmacology (IUPHAR), GPR55 is 
still an ophan GPCR. However, several reports su-
ggest that L-α-lysophosphatidylinositol (LPI) is a 
potential endogenous receptor ligand. Thus, Oka 
and coworkers reported that GPR55 is engaged 
Introduction
23
by LPI in a model of ectopic overexpression of the 
receptor in HEK293 cells (Oka et al., 2007). This 
observation was corroborated by other reports in 
different cell types (Henstridge et al., 2009; Ka-
pur et al., 2009; Lauckner et al., 2008; Oka et al., 
2010; 2009; Whyte et al., 2009; Yin et al., 2009). 
Specifically, 2-arachidonoyl-LPI species have 
been described as the most efficient and potent 
in activating GPR55 (Oka et al., 2009). 
But LPI is not the only ligand paired with 
GPR55. Few years after its identification and clo-
ning, two different patents described the receptor 
as a putative cannabinoid receptor (Baker et al., 
2006). Cannabinoids were originally described 
as the active compounds of the plant Cannabis 
sativa, but nowadays the term cannabinoids also 
includes the endogenous compounds produced 
by animals -the so called endocannabinoids- and 
synthetic molecules (Pertwee et al., 2010a). Can-
nabinoids mediate most of their effects by bin-
ding to and activating specific GPCRs. So far, two 
bona-fide cannabinoid receptors have been clo-
ned, CB1 (highly expressed in the central nervous 
system) (Matsuda et al., 1990) and CB2 (mostly 
expressed in the immune system) (Munro et al., 
1993). Different evidences have suggested that 
other non-CB1/non-CB2 cannabinoid receptor 
exist, being GPR55 one of the candidates (Mac-
kie and Stella, 2006; Pertwee et al., 2010b; Ross, 
2009). First, a patent from GlaxoSmithKline des-
cribed the activation of GPR55 in yeast by AM251 
and SR141716A, two well-established CB1 recep-
tor antagonists. A second patent from AstraZe-
neca described that the synthetic cannabinoid 
CP-55940, the endocannabinoids anandamide 
(AEA), 2-arachidonoylglycerol (2-AG), the marijua-
na-derived cannabinoid Δ9-tetrahydrocannabinol 
(THC) and the cannabinoid-related compounds 
virodhamina and palmitoylethanolamide (PEA) 
were potent agonists on GPR55 in a model of 
membranes derived from HEK293 cells (Baker et 
al., 2006). However, whether GPR55 can be con-
sidered a cannabinoid receptor is still a controver-
sial issue (Ross, 2009; Sharir and Abood, 2010). 
First, GPR55 shares low amino acid sequence 
identity with CB1 (13.5%) and CB2 (14.4%) (Box 
2), and second, and most importantly, there is 
no consistency among studies on whether and 
which cannabinoids activate GPR55. For exam-
ple, while some studies have shown that AEA and 
Box 2. GPR55 structural peculiarities and 
divergences with CB1 and CB2 receptor. The 
structure of GPR55 contains most of the highly 
conserved residues of the class A GPCRs and 
cannabinoid receptors, but presents some inter-
esting peculiarities. For example, the binding poc-
ket of GPR55 is lined with hydrophilic residues al-
most to the intracellular side of the receptor, with 
a Lys80 residue essential for GPR55 ligand re-
cognition (Elbegdorj et al., 2013). In contrast, CB1 
and CB2 receptors present highly hydrophobic 
binding pockets (Gasperi et al., 2013; Kotsikorou 
et al., 2011). Another relevant difference is in the 
TM7 region. Like LPA4, LPA5 and LPA6 receptors, 
GPR55 lacks the highly conserved NPXXY motif 
(present in CB1 and CB2 receptors), and has a 
DVXXY sequence instead that produces different 
hydration and local transmembrane flexibility, and 
in the end, a different conformation in this region 
(Kotsikorou et al., 2011). It has been described 
that class A GPCRs present a cholesterol binding 
site defined by a higly conserved consensus mo-
tif (CCM). Sequence analysis showed that GPR55 
and CB1, in contrast with CB2, do not contain 
CCM, suggesting that these receptors might con-
tain other motifs responsible for interaction with 
cholesterol and lipid rafts. On the other hand, cho-
lesterol recognition amino acid consensus motifs 
(CRAC) are presented and located in GPR55 in 
the same region as in CB1 and CB2 receptors, [i.e., 
at the level of TM7 (Gasperi et al., 2013)].  All the-
se differences may explain, at least in part, the 
different ligand activation and biological activity 
of GPR55, CB1 and CB2 receptors.
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2-AG behave as GPR55 agonists (Lauckner et al., 
2008; Ryberg et al., 2007; Waldeck-Weiermair et 
al., 2008), other authors did not find any effect of 
these compounds via GPR55 (Kapur et al., 2009; 
Oka et al., 2007). The same occurs with other 
cannabinoids, such as THC, CP-55940 or JWH-
015 (Sharir and Abood, 2010). In this controver-
sial pharmacological scenario, it is widely accep-
ted however that the synthetic CB1 antagonists 
AM251 and SR141716A are GPR55 agonists (Ba-
lenga et al., 2011; Henstridge et al., 2009; Kapur 
et al., 2009; Kargl et al., 2012; Kotsikorou et al., 
2011), and that cannabidiol (CBD), a plant-deri-
ved cannabinoid with very low affinity for classi-
cal cannabinoid receptors, is a GPR55 antagonist 
(Balenga et al., 2011; Ford et al., 2010; Ryberg et 
al., 2007; Whyte et al., 2009).
The inconsistences on GPR55 pharmacology 
may rely on tissue, cell type and context, but they 
could also be explained by the specific characte-
ristics of GPCRs. First, it has been shown that GP-
CRs can be in different active conformation states 
and that ligands present different affinity for these 
conformational states, which lead to the activa-
tion of different intracellular signaling pathways 
(Park, 2012). Another possible explanation is the 
“biased agonism”, by which certain ligands can 
trigger non-G protein signaling pathways, activa-
ting only a subset of effectors (Audet and Bouvier, 
2012; Venkatakrishnan et al., 2013). In addition, it 
has been described that GPCRs can form oligo-
mers that modulate their individual functions, ac-
tivating different and specific signaling pathways 
(Audet and Bouvier, 2012; Ferré et al., 2009). In 
line with this idea, a functional interaction between 
Figure 5. Signaling pathaways activated by GPR55. GTP, guanosine 5’-triphosphate ; PI3K, phosphatidylinositol 3-ki-
nase ; Bmx, bone marrow kinase X; PLC, phospholipase C; DAG, diacylglycerol; IP3,  inositol 1,4,5-trisphosphate; ER, 
endoplasmic reticulum; NFAT, nuclear factor of activated T-cells; NFkB, nuclear factor kappa-light-chain-enchancer of 
activated B cells; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase.
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GPR55 and CB2 receptor has been described in 
neutrophils (Balenga et al., 2011), and an interac-
tion between CB1 receptors and GPR55 has been 
reported in a HEK293-based model (Kargl et al., 
2012). Kargl and coworkers showed that the ac-
tivation of ERK, nuclear factor of activated T-cells 
(NFAT) and serum-response element (SRE) indu-
ced by activation of GPR55 by SR141716A and 
GSK319197A (a proposed GPR55 synthetic ago-
nist) is not evident in the presence of an inactive 
CB1 receptor. On the contrary, if both receptors 
are activated, CB1 internalizes and GPR55 is able 
to signal (Kargl et al., 2012). 
GPR55 signaling pathways
The mechanism by which GPR55 transforms 
an external stimulus into a biological response 
has been studied in different cellular models such 
as endothelial cells, osteoclasts, large dorsal root 
ganglion or tumoral cells. All the studies conclu-
de that, while CB1 and CB2 signal mostly via Gi/o, 
GPR55 couples preferentialy to G12/13 [with the 
subsequent activation of RhoA (Balenga et al., 
2011; Brown et al., 2011; Henstridge et al., 2009; 
Huang et al., 2011; Lauckner et al., 2008; Obara 
et al., 2011; Oka et al., 2010; Ryberg et al., 2007)] 
and/or Gq [producing the activation of PLC (Lauc-
kner et al., 2008; Obara et al., 2011; Waldeck-
Weiermair et al., 2008)]. 
By engaging either G protein, GPR55 activa-
tes different signalling pathways, including MAPK 
cascades, cytoplamsic Ca2+ increase or actin fi-
lament formation. In HEK293 cells, Henstridge 
and coworkers described that the activation of 
GPR55 induces an oscillatory Ca2+ release from 
intracellular stores via G12/13/RhoA/ROCK, with the 
subsequent phosphorylation and activation of the 
ERK/MAPK cascade and activation of transcrip-
tion factors such as NFAT or nuclear factor kappa-
light-chain-enchancer of activated B cells (NFkB), 
that translocate to the nucleus and modulate the 
expression of different genes (Henstridge et al., 
2009; 2010). Other authors have described similar 
pathways in other cell types like dorsal root gan-
glia neurons (Lauckner et al., 2008), neutrophils 
(Balenga et al., 2011) or osteoclasts (Whyte et al., 
2009). Other studies have revealed that GPR55, 
also via G12/13, is able to activate the p38/MAPK 
cascade and the activating transcription factor 
2 (ATF-2) in IM9 lymphoblastoid cells (Oka et al., 
2010), and to istimulate JNK in cholangiocarcino-
ma calls (Huang et al., 2011) (figure 5). 
Coupling of GPR55 to Gq modulates alterna-
tive signalling pathways. Thus, GPR55 activates 
PLC, releasing IP3 (with the subsequent increase 
of intracellular Ca2+), and DAG (in charge of ac-
tivating PKC and different MAPKs) (Lauckner et 
al., 2008; Obara et al., 2011). In endothelial cells, 
Waldeck-Weiermair and coworkers described 
that GPR55, via Gq, triggers the PI3K-bone ma-
rrow kinase X-linked (Bmx)-PLC cascade, with 
IP3 production and intracellular Ca2+ mobilization 
(Waldeck-Weiermair et al., 2008).
GPR55 physio-pathology
GPR55 is widely expressed throughout the 
body. Its mRNA and/or protein have been found in 
different regions of the brain such as caudate, pu-
tamen, frontal cortex, striatum and hypothalamus 
(Sawzdargo et al., 1999), as well as in glial cells 
(Pietr et al., 2009) and large dorsal root ganglia 
neurons (Lauckner et al., 2008). GPR55 is also 
expressed in peripheral tissues including spleen, 
adrenal glands, gastrointestinal tract (Ryberg et 
al., 2007; Sawzdargo et al., 1999), bone (Whyte 
et al., 2009), liver (Huang et al., 2011), pancreas 
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(Romero-Zerbo et al., 2011), kidney (Jenkin et al., 
2010), endothelial cells (Daly et al., 2010; Wal-
deck-Weiermair et al., 2008; Zhang et al., 2010), 
vascular smooth muscle cells (Daly et al., 2010; 
Fonseca et al., 2011), neutrophils (Balenga et al., 
2011) and mastocytes (Cantarella et al., 2011a), 
suggesting that it may be involved in the control 
of many different biological functions (figure 6).  
GPR55 has been implicated in the control of 
pain. Thus, activation of this receptor enhances 
neuronal excitability by increasing intracellular 
Ca2+ and suppressing the K+ current acting on M-
type channels (Lauckner et al., 2008). These data 
point to a pro-nociceptive role of GPR55. In line 
with this idea, GPR55 deficient mice, unlike their 
WT counterparts, do not show hyperalgesia upon 
inflammatory or neuropathic stimuli (Staton et al., 
2008). This was related to an abnormal increase 
of cytokines like IL-4, IL-10, interferon (IFN)-γ and 
granulocyte macrophage-colony stimulating fac-
tor (GM-CSF) in GPR55 KO mice after noxious 
stimulation. The role of GPR55 in inflammation is 
further supported by studies performed in micro-
glial cells. For example, GPR55 expression chan-
ges during primary microglia cell activation. Lipo-
polysaccharide (LPS) or IFN-γ treatment induce 
a significant downregulation of GPR55 mRNA 
levels in primary microglia, while both activators 
induce GPR55 overexpression in an immortalized 
Figure 6. Patho-physiological relevance of GPR55. In the mouse nervous system, GPR55 regulates dorsal root gan-
glia excitability,  neurite elongation, hippocampal CA3-CA1 single synapse, controls inflammatory and neuropathic pain 
and microglia activation. In blood, GPR55 regulates neutrophil migration and may prevent oxidative damage. GPR55 is 
also involved in bone metabolism, inducing bone resorption. Other studies have suggested additional roles for GPR55 in 
modulating vascular function [by inducing vasorelaxation and controlling angiogenesis, renal tubule hypertrophy, decidual 
tissue regression during pregnancy, and mast cell-mediated anti-inflammatory actions]. GPR55 also controls intestinal 
movements and energy metabolism by regulating insulin release and glucose tolerance by the langerhans islets. Figure 
adapted from (Henstridge et al., 2011). 
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and highly proliferative cell line (BV-2) (Pietr et al., 
2009). 
These reports suggest an involvement of 
GPR55 in inflammation within the central nervous 
system (CNS). But a role for GPR55 in the immu-
ne response in the periphery has also been des-
cribed. GPR55 is expressed in neutrophils, where 
it functionally interacts with CB2, also expressed 
in these cells (Balenga et al., 2011). Activation of 
both receptors produces a cooperative induction 
of neutrophil chemotaxis, involving the synergic 
activation of RhoA and Cdc42, which results in an 
enhanced migratory response to the inflammatory 
foci (Balenga et al., 2011). In addition, GPR55 re-
gulates the excessive generation of reactive oxy-
gen species produced by CB2 agonists in these 
cells, controlling CB2-mediated oxidative damage 
(Balenga et al., 2011). The expression of GPR55 
has also been reported in mastocytes, where it 
seems to play an anti-inflammatory role.  Activa-
tion of GPR55 in these cells blocks the release 
of nerve growth factor (NGF), a factor induced by 
inflammatory agents (Cantarella et al., 2011a). A 
recent study described GPR55 expression in ute-
rine natural killer cells, suggesting an involvement 
of GPR55 in the immunological reactions during 
pregnancy. The authors also observed that acti-
vation of GPR55 in these cells induces decidual 
cell death, suggesting a role of GPR55 in fetopla-
cental development (Fonseca et al., 2011). 
Although GPR55 is expressed in the CNS, the 
lack of the receptor does not alter gross brain 
structures or CNS development (Wu et al., 2013). 
Thus, general behavioural  responses, gross mo-
tor skills, sensory-motor integration, learning and 
memory or anxiety and depressive behaviors are 
not modified in GPR55 KO mice. However, in 
more challenging motor responses, GPR55 defi-
cient mice present impaired movement coordina-
tion (Wu et al., 2013). Supporting the involvement 
of GPR55 in the control of central functions, it has 
been shown that GPR55 regulates neurite elon-
gation. The authors reported that LPI, via GPR55-
G12/13-RhoA, produces neurite retraction, accom-
panied by loss of light chain neurofilaments and 
redistribution of F-actin in differentiated cells. This 
effect was accompanied by the localization of the 
receptor in growth cones or ruffled borders in di-
fferenciated neurons (Obara et al., 2011). A recent 
study has described the involvement of GPR55 
in synaptic circuits, specifically in hippocampal 
single CA3-CA1 synapses (Sylantyev et al., 2013). 
GPR55 activation induces intracellular Ca2+ relea-
se from presynaptic stores that prompts a tran-
sient increase in release probability at CA3-CA1 
synapses (Sylantyev et al., 2013). 
GPR55 has also been implicated in bone phy-
siology. In vitro activation of GPR55 by LPI stimu-
lates osteoclast polarization and resorption acti-
vity. A similar effect was observed in vivo, where 
male GPR55 KO mice presenting a decreased 
bone resorption associated with high bone mass 
and an osteopetrotic phenotype (Whyte et al., 
2009). 
Recent studies propose that GPR55 controls 
intestinal movements (Lin et al., 2011; Ross et al., 
2012) and energy metabolism. GPR55 is highly 
expressed in pancreatic islets and insulin-secre-
ting β-cells. GPR55 activation in Langerhans is-
lets in vitro produces an increase in intracellular 
Ca2+ and glucose-dependent insulin secretion. 
Moreover, in vivo activation of GPR55 enhances 
glucose tolerance and the levels of insulin in plas-
ma (Romero-Zerbo et al., 2011). Interestingly, high 
levels of GPR55 are associated with visceral adi-
posity and type-2 diabetes, and obese patients 
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present higher circulating levels of LPI than lean 
individuals (Moreno-Navarrete et al., 2012).
It has been suggested that GPR55 may regu-
late vascular functions as well. Thus, GPR55 is 
expressed by vascular endothelial cells, and the-
se cells produce LPI, the putative GPR55 endo-
genous ligand (Bondarenko et al., 2010; Brown, 
2007; Daly et al., 2010; Johns et al., 2007; Ry-
berg et al., 2007; Waldeck-Weiermair et al., 2008). 
However, although many reports have studied the 
role of GPR55 in the vasculature, there are not 
convincing results establishing a direct link bet-
ween the two elements. Many studies have repor-
ted the presence of a non-CB1/non-CB2  canna-
binoid-sensitive vascular receptor that could be 
regulating the vasodilating effects of some can-
nabinoids such as AEA and abnormal cannabidiol 
(abn-CBD)(Kreitzer and Stella, 2009). The presen-
ce of GPR55 in endothelial cells and its activation 
by AEA and abn-CBD (Ryberg et al., 2007) point 
to this receptor as a likely candidate to constitute 
the non-CB1/non-CB2 receptor in the vasculature 
that mediates those effects. However, blood pres-
sure and heart rate were similar in GPR55 KO and 
WT mice. Moreover, there were no differences 
in the vascular relaxation induced by abn-CBD 
in GPR55 KO and WT mice (Johns et al., 2007), 
suggesting that, although GPR55 is present in 
the vasculature, it is not the site of action of abn-
CBD. GPR55 signaling in endothelial cells might 
be controlled by the cellular context. Thus, Wal-
deck-Weiermair and coworkers have suggested a 
possible downstream interaction between GPR55 
and CB1 in endothelial cells, conditioned by this 
cellular context. In this case, depending on the 
clustering state of the integrins, AEA, a ligand for 
both receptors, activates one receptor, inhibiting 
the other, or vice versa (Waldeck-Weiermair et al., 
2008). A recent report, however, confirms a role 
for GPR55 in vascular functions, specifically in 
angiogenesis. Thus, activation of the receptor sti-
mulates tube formation, endothelial cell migration 
and upregulation of the angiogenesis inducing 
signal VEGF (Zhang et al., 2010).
Different indirect evidences suggest that 
GPR55 could be involved in cancer physio-pa-
thology. First, increased levels of LPI, the putati-
ve GPR55 endogenous ligand, have been found 
in plasma and ascites from patients with ovarian 
cancer compared with women without oncoge-
nic pathologies (Sutphen et al., 2004b; Xiao et 
al., 2001). Moreover, epithelial cells (Falasca and 
Corda, 1994) and fibroblasts (Falasca et al., 1998) 
are able to generate mitogenic LPI after Ras in-
duced transformation. Second, GPR55 couples 
to G12/13 and Gq, which are known to have onco-
genic properties (Dorsam and Gutkind, 2007; Wu 
et al., 2012). For example, overexpression of the 
G12/13 stimulates mitogenic signals that induce fi-
broblast transformation (Dhanasekaran and Der-
mott, 1996). Moreover, GPR55 signals through 
Rho GTPases, which control cytoskeleton organi-
zation, cell polarity and cell migration, all of them 
intimatelly related to tumor progression (Karlsson 
et al., 2009). Finally, certain cannabinoids -com-
pounds with known antitumoral actions (Velas-
co et al., 2012)-  can activate GPR55 (Sharir and 
Abood, 2010), suggesting that this receptor may 
be part of a system that controls tumor generation 
and/or progression. 
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Since the orphan G protein-coupled receptor GPR55 was first cloned in 1999, different laboratories 
started to analyze the physiological relevance and mechanism of action of this receptor. Although almost 
15 years later little is still known about these two issues, it has been proposed that GPR55 regulates res-
ponses in the central nervous system, bone, immune system and vasculature, among others, and that 
most GPR55-mediated effects are produced via coupling to Gq and G12/13 proteins. Considering that (a) 
some GPCRs are associated to cancer, (b) signaling properties of GPR55 and (c) that lysophospholipids 
and cannabinoids (two putative families of GPR55 ligands) play important roles in cancer, the working 
HYPOTHESIS of this Thesis is that GPR55 participates in the control of tumor physio-pathology. 
In this context, the spefic AIMS of this study are:
1. To study the expression of GPR55 in human tumors.
2. To investigate the role of GPR55 in tumor generation and progression.
3. To analyze whether GPR55 is involved in the effect of cannabinoids on cancer cell proliferation.
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CHAPTER 1
In this first chapter we will try to determine whe-
ther GPR55 plays any significant role in cancer 
physiopathology. First, we will analyze the expres-
sion of GPR55 in a collection of human tumor cell 
lines and human breast cancer, glioblastoma and 
pancreatic adenocarcinoma samples. In addition, 
we will modulate GPR55 expression in cancer cell 
lines (by transfection with HA-GPR55 constructs 
or genetic knock-down with specific siRNAs) to 
determine the involvement of GPR55 in cancer 
cell proliferation both in vitro and in vivo. We will 
also try to characterize the molecular mecha-
nisms underlying GPR55 action on cancer cells. 
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SHORT COMMUNICATION
The orphan G protein-coupled receptor GPR55 promotes cancer cell
proliferation via ERK
C Andradas, MM Caffarel1, E Pe´rez-Go´mez, M Salazar, M Lorente, G Velasco, M Guzma´n
and C Sa´nchez
Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain
GPR55 is an orphan G protein-coupled receptor that may
be engaged by some lipid ligands such as lysophosphati-
dylinositol and cannabinoid-type compounds. Very little is
known about its expression pattern and physio-pathological
relevance, and its pharmacology and signaling are still
rather controversial. Here we analyzed the expression and
function of GPR55 in cancer cells. Our data show that
GPR55 expression in human tumors from different origins
correlates with their aggressiveness. Moreover, GPR55
promotes cancer cell proliferation, both in cell cultures and
in xenografted mice, through the overactivation of the
extracellular signal-regulated kinase cascade. These find-
ings reveal the importance of GPR55 in human cancer, and
suggest that it could constitute a new biomarker and
therapeutic target in oncology.
Oncogene (2011) 30, 245–252; doi:10.1038/onc.2010.402;
published online 6 September 2010
Keywords: G protein-coupled receptors; GPR55; cancer;
cannabinoids
G protein-coupled receptors (GPCRs) constitute the
largest superfamily of cellular receptors. They control
crucial physiological functions and, consequently, their
dysfunction contributes to many human diseases. In
fact, they are—together with enzymes—the most common
target of therapeutic drugs (Dorsam and Gutkind,
2007). Deorphanizing GPCRs and expanding our
knowledge on GPCR-mediated signaling pathways is
therefore a pivotal strategy to design new diagnostic and
therapeutic tools for human pathologies. It has been
recently proposed that the orphan GPCR GPR55 is
engaged and activated by lysophosphatidylinositol
(LPI) (Oka et al., 2007). This original observation, made
in cells ectopically expressing GPR55, was shortly
corroborated by other reports (Lauckner et al., 2008;
Henstridge et al., 2009; Kapur et al., 2009; Oka et al.,
2009, 2010; Yin et al., 2009). Moreover, LPI has been
found to activate GPR55 in cells in which the receptor
is endogenously expressed (large dorsal root ganglion
neurons (Lauckner et al., 2008), osteoclasts (Whyte et al.,
2009) and lymphoblastoid cells (Oka et al., 2010)),
supporting the notion that this phospholipid may be an
endogenous GPR55 ligand. Nonetheless, all the func-
tions described so far for LPI on GPR55 come from
experiments in which LPI was exogenously added to the
cultured cells, and therefore evidence for the role of the
naturally occurring lipid in more physiological settings is
still missing. It has also been shown that several
cannabinoid-type compounds modulate this receptor
(Ryberg et al., 2007; Lauckner et al., 2008; Waldeck-
Weiermair et al., 2008; Henstridge et al., 2009, 2010;
Kapur et al., 2009; Yin et al., 2009). However, the
inconsistencies among the pharmacological results
obtained so far (some compounds being active in some
reports and inactive in others, some being agonists in
some studies and antagonists in others, and so on) do
not entirely clarify whether GPR55 is an actual
cannabinoid receptor (Brown and Robin Hiley, 2009;
Ross, 2009). GPR55 mRNA is highly expressed in the
brain, the adrenal glands, parts of the gastrointestinal
tract, spleen, tonsils, testes, thymus (Sawzdargo et al.,
1999; Ryberg et al., 2007; Oka et al., 2010), large dorsal
root ganglion neurons (Lauckner et al., 2008), osteo-
clasts (Whyte et al., 2009), certain microglial cells (Pietr
et al., 2009), endothelial cells and mesenteric arterial
smooth muscle cells (Daly et al., 2010), but very little is
known about the physiological role of the receptor in
these or other tissues. To date, GPR55 has been
implicated in the control of pain, specifically in the
mechanical hyperalgesia induced by inflammatory and
neuropathic pain (Staton et al., 2008), and in the control
of bone formation (Whyte et al., 2009). Its wide distri-
bution throughout the body suggests, however, that
GPR55 might be involved in many other biological
functions. As some GPCRs have a prominent role in
cancer cell biology (Dorsam and Gutkind, 2007) and,
more specifically, GPR55 has been shown to couple to
G12/13 and Gq proteins (Ryberg et al., 2007; Lauckner
et al., 2008; Henstridge et al., 2009), which drive
oncogenic signaling (Dorsam and Gutkind, 2007;
Worzfeld et al., 2008), we sought to analyze the physio-
pathological relevance of this receptor in the context
of cancer.
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published online 6 September 2010
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Supplemental Table 1
C. Andradas et al.
Cell line Origin GPR55expression Cell line Origin
GPR55
expression
A172 Glioblastoma + BT-474 Breast ductal carcinoma +
CCF-STTG1 Astrocytoma ++ EVSA-T Breast adenocarcinoma ++
GOS-3 Astrocytoma/Oligodendroglioma ++ MCF-7 Breast adenocarcinoma +
H4 Neuroglioma + MDA-MB-231 Breast adenocarcinoma +
LN-405 Astrocytoma ++ MDA-MB-468 Breast adenocarcinoma +
SW 1088 Astrocytoma + SK-BR-3 Breast adenocarcinoma -
SW 1783 Astrocytoma + T-47D Breast ductal carcinoma -
T98G Astrocytoma ++ A-375 Melanoma ++
U-87 MG Astrocytoma + HeLa Cervix adenocarcinoma +
U-118 MG Astrocytoma + Hep-G2 Hepatocellular carcinoma +
U-373 MG Astrocytoma + JURKAT T cell leukemia +
IM-9 B lymphoblastoid myeloma ++
MIA PaCa-2 Pancreas carcinoma +
Table S1. Human cancer cell lines express GPR55 mRNA. Human cell lines were
obtained from The American Type Culture Collection (Manassas, VA) and the German
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). RNA
was isolated with Trizol Reagent (Invitrogen, Carlsbad, CA), including a DNase digestion
step, with the Real Star Kit (Durviz, Valencia, Spain), and cDNA was obtained with
Transcriptor Reverse Transcriptase (Roche, Basel, Switzerland). The primers used for real
time-quantitative PCR for human GPR55 were: sense 5’-CTGCCTTGGTTCCACCATA-3’
and antisense 5’-CCAGGATGCAGGTGAGTAAGA-3’. The probe was from the Universal
Probe Library (Roche). 18S RNA was used as reference.
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Supplemental Figure 1
C. Andradas et al.
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Figure S1. Characterization of GPR55-overexpressing HEK293 cells. HEK293
cells stably expressing 3xHA-GPR55 were previously generated (Henstridge et al.,
2009) (A) Western blot analysis of HA-tagged GPR55 Antibodies were: anti-HA. .
(Cell Signaling Technology, Danvers, MA) and anti--tubulin (used as loading
control, Sigma-Aldrich, St. Louis, MO). (B) GPR55 mRNA expression as determined
by RT-PCR. Primers were: sense 5’- GTCCCCCTTCCCGTCCCTGTG-3’ and
antisense 5’- GCTGGCTGCGATGCTGTAGATGC-3’. GAPDH was used as internal
control. (C) Immunofluorescence analysis of GPR55 expression by anti-HA staining
(in green). Cell nuclei (in blue) were stained with Hoechst 33342 (Invitrogen,
Carlsbad, CA). Scale bar, 4µm.
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Supplemental Figure 2
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Figure S2. Immunofluorescence analysis of CD31 staining in T98 cells-derived
xenografts The potential antiangiogenic effect of GPR55 silencing in vivo was
C
D
3
.
determined by immunofluorescence analysis of the vascular endothelial marker
CD31. Tissue-tek embedded paraformaldehyde fixed tumor sections were incubated
with anti-CD31 antibody (Pharmingen/BD Biosciences, San Jose, CA). The
secondary anti-rabbit Alexa Fluor 594 antibody was from Invitrogen (Carlsbad, CA).
Cell nuclei were stained with Hoechst 33342 (Invitrogen) and are shown in blue.
Confocal fluorescence images were acquired using Laser Sharp 2000 software (Bio-
Rad) and CD31 staining intensity (expressed in arbitrary units, mean ± s.e.m.) was
calculated with ImageJ software (n= 4 animals per group, 8 sections per animal).
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Supplemental Figure 3
C. Andradas et al.
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Figure S3. Inhibition of LPI synthesis prevents GPR55-induced
increase in cell proliferation. HEK293 cells stably expressing 3xHA-
GPR55 (HEK-GPR55) or the corresponding empty vector (HEK) were
serum-starved overnight and incubated with the PLA2 inhibitor
pyrrophenone (Pyr, 1 µM, generously donated by Dr. Balsinde,
Instituto de Biología y Genética Molecular, Valladolid, Spain) or
vehicle (Veh) for 48 h. Cell viability was determined by the MTT test.
R lt d % th ll i bilit f hi l t t desu s are expresse as vs e ce v a y o ve c e- rea e
HEK293 cells, set at 100%. *, p<0.05 vs vehicle-treated HEK293
cells; #, p<0.05 vs vehicle-treated HEK293-GPR55 cells; n=3.
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CHAPTER 2
In this second chapter, we will study in more de-
tail the role of GPR55 in tumor generation and 
progression. To achieve this goal, we will use the 
well-established model of chemically-induced 
skin carcinogenesis in mice lacking GPR55 and 
their corresponding wild type littermates. We will 
study the effects of deleting GPR55 on malignant 
transformation, and we will also try to unravel the 
molecular bases of such effects. Finally, we will 
analyze the expression of GPR55 in different hu-
man squamous cell carcinomas and we will try to 
determine whether this expression correlates with 
markers with clinical relevance.  
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ORIGINAL ARTICLE
The orphan receptor GPR55 drives skin carcinogenesis
and is upregulated in human squamous cell carcinomas
E Pe´rez-Go´mez1, C Andradas1, JM Flores2, M Quintanilla3, JM Paramio4, M Guzma´n1,5 and C Sa´nchez1
G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human
diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known
about its physio-pathological relevance. It has been recently shown that GPR55 controls the behavior of human cancer cell lines in
culture and xenografts. However, the assessment of the actual role of this receptor in malignant transformation in vivo is hampered
by the lack of studies on its functional impact in clinically-relevant models of cancer. Here we demonstrate that GPR55 drives mouse
skin tumor development. Thus, GPR55-deficient mice were more resistant to DMBA/TPA-induced papilloma and carcinoma
formation than their wild-type littermates. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advantage on
cancer cells. In addition, GPR55 enhanced skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo,
suggesting that it promotes not only tumor development but also tumor aggressiveness. Finally, we observed that GPR55 is
upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues.
Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and suggest that this receptor may
be used as a new biomarker and therapeutic target in squamous cell carcinomas.
Oncogene (2013) 32, 2534–2542; doi:10.1038/onc.2012.278; published online 2 July 2012
Keywords: GPR55; G protein-coupled receptors; skin carcinogenesis; squamous cell carcinoma; cannabinoids
INTRODUCTION
G protein-coupled receptors (GPCRs) are the direct or indirect
target of 450% of current therapeutic drugs. In the context of
oncology, however, despite the increasing evidence showing a
link between GPCR deregulation and cancer, just a few GPCRs are
being exploited as targets of chemotherapeutic agents. Indirect
lines of evidence suggest that the orphan GPCR GPR55 may have
a role in cancer physiopathology. Thus, increased levels of the
phospholipid lysophosphatidylinositol (LPI), a putative GPR55
endogenous ligand,1 have been found in plasma and ascites
from patients with ovarian cancer compared with healthy women
or with women with non-cancerous pathologies.2,3 In addition,
epithelial cells4 and fibroblasts5 are able to generate mitogenic LPI
upon ras-driven transformation. More recently, it has been shown
that GPR55 modulates cancer cell migration6 and proliferation7,8
in vitro, and tumor growth in a xenograft-based model of
glioblastoma.7 However, the actual role of GPR55 in malignant
transformation in vivo remains unknown. One of the best
established paradigms for studying the mechanisms underlying
this process is the mouse skin model of two-stage carcinogenesis.9
Animals subjected to this experimental protocol evolve
through different stages of cancer progression: first, in the
‘initiation’ phase, key genes are mutated in keratinocyte stem
cells by topical exposure to the mutagenic agent 7,12-
dimethylbenz[a]anthracene (DMBA).9 After the initiation stage,
the population of mutated cells expands as a result of the
repeated topical application of a proliferation-inducing agent such
as the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA),
UV radiation or wounding. During this ‘promotion’ stage, animals
develop benign hyperplastic skin lesions termed papillomas.9 With
variable frequency these structures may progress to malignant
invasive squamous cell carcinomas or the more aggressive spindle
cell carcinomas. This ‘progression’ stage occurs independently
of tumor promoters and is the consequence of the genetic
alterations accumulated during the proliferation of initiated cells.9
Here, by using this experimental protocol, as well as other in vivo
and in vitro approaches, we demonstrate that GPR55 has an
essential role in skin tumor development.
RESULTS
GPR55 is expressed in mouse epithelia
First, we analyzed the expression of GPR55 in different mouse-
stratified epithelia. As shown in Supplementary Figure 1, the
receptor was moderately expressed in mouse skin, specifically in
the epidermis (Supplementary Figure 1A). A similar pattern of
GPR55 expression was found in other mouse-stratified epithelia.
Thus, a discreet GPR55 immunoreactivity was detected in the
epithelial compartments of the oral cavity (Supplementary
Figure 1B), esophagus (Supplementary Figure 1C) and stomach
(Supplementary Figure 1D). Interestingly, GPR55-positive cells
were mainly located in the most proliferative layers of those
epithelia (Supplementary Figure 1). Controls of the specificity of
GPR55 staining are provided in Supplementary Figure 2.
1Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain; 2Department of Animal Surgery and Medicine, School of
Veterinary, Complutense University, Madrid, Spain; 3Instituto de Investigaciones Biome´dicas Alberto Sols, Consejo Superior de Investigaciones Cientı´ficas, Universidad Auto´noma
de Madrid, Madrid, Spain; 4Molecular Oncology Unit, Division of Biomedicine, CIEMAT, Madrid, Spain and 5Centro de Investigacio´n Biome´dica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED) and Instituto Ramo´n y Cajal de Investigacio´n Sanitaria, Madrid, Spain. Correspondence: Dr C Sa´nchez, Department of Biochemistry and Molecular
Biology I, School of Biology, Complutense University, C/ Jose´ Antonio Novais, 2, 28040, Madrid, Spain.
E-mail: cristina.sanchez@quim.ucm.es
Received 22 March 2012; revised and accepted 21 May 2012; published online 2 July 2012
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Supplementary Fig. S1
A
DB
C
FD
Supplementary Fig. S1 Expression of GPR55 in mouse
stratified epithelia Immunohistochemical analysis of GPR55 in.
mouse skin (A), oral cavity (B), esophagus (C) and stomach (D).
Right images represent magnifications of the selected areas.
GPR55 appears in brown and cell nuclei in blue. Scale bars, 200
m.
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Supplementary Fig. S2
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Immunohistochemical staining of GPR55 in papillomas generated in the skin 
of wild type (WT) and GPR55-deficient (GPR55 KO) mice. GPR55 appears 
in brown and cell nuclei in blue.
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Supplementary Fig. S2
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Immunofluorescence staining of GPR55 in papillomas generated in the skin of wild type 
(WT) and GPR55 deficient (GPR55 KO) mice GPR55 appears in green and cell nuclei
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in blue.
Results and Discussion
67
C Anti-GPR55
Anti-GPR55 + 
blocking peptide
Pérez-Gómez et al.
Supplementary Fig. S2
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Immunofluorescence staining of GPR55 in a papilloma generated in the skin of a wild 
type mouse Left panels sections were incubated with anti GPR55 antibody Right  .  ,     -  .  
panels, sections were incubated with the anti-GPR55 antibody preincubated with the 
corresponding blocking peptide. GPR55 appears in green and cell nuclei in blue.
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Supplementary Fig. S3
0h
GPR55 Cell nuclei Merge
48h
Supplementary Fig. S3 GPR55 is upregulated upon TPA-treatment. Wild type mice 
were treated topically with a single TPA application. GPR55 expression in the skin was 
analyzed by immunofluorescence at the indicated times.  
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Supplementary Fig. S4
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Supplementary Fig. S4 GPR55 mediates TPA-induced dermal inflammation. Wt
and GPR55 KO mice received a single topical application of the tumor promoter TPA.
Immunofluorescence analysis (A) and quantification (B) of CD45-positive (green) cells
(differentiated hematopoietic cells except erythrocytes and platelets) 72 h after TPA
application. Cell nuclei are in blue. Results are expressed as % vs total cells per field. C
and D, Real-time quantitative PCR analysis of IL-β1 (C) and TNF-α (D) mRNA, in the
skin of wt and KO mice at the indicated times after TPA application. Results are
expressed in arbitrary units. **, p<0,01 vs t0 (time of TPA application); ##, p<0,01 vs the
corresponding group of wt mice.
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Supplementary Table S1. Primers used for reverse-transcriptase (RT) and real-time 
quantitative (RTQ) PCR 
 
RT-PCR 
primers Sense Antisense 
mGPR55 5′-GTGGTCTCCTTTCTCCCAGTG-3′ 5′-TTAGCCCCTGGAGACCATGGTATCC-3′ 
mc-Fos 5′-AGCATGGGCTCTCCTGTCAA-3′ 5′-GGGCTGCCAAAATAAACTCC-3′ 
GAPDH 5′-GGGAAGCTCACTGGCATGGCCTTCC-3′ 5′-CATGTGGGCCATGAGGTCCACCAC-3′ 
   
RTQ-PCR 
primers Sense Antisense 
hGPR55 5′-CTGCCTTGGTTCCACCATA-3′ 5′-CCAGGATGCAGGTGAGTAAGA-3′ 
mGPR55 5′-TGGCCAGGCATCTTCAGT-3′ 5′-CCAAGAGAAGTCCCCTTTCC-3′ 
mIL1 5′-TGTAATGAAAGACGGCACACC-3′ 5′-TCTTCTTTGGGTATTGCTTGG-3′ 
mTNF 5′-TGCCTATGTCTCAGCCTCTTC-3′ 5′-GAGGCCATTTGGGAACTTCT-3′ 
18S 5′-GCTCTAGAATTACCACAGTTATCCAA-3′ 5′-AAATCAGTTATGGTTCCTTTGGTC-3′ 
  
Results and Discussion
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CHAPTER 3
In this third chapter, we will investigate whether 
GPR55 participates in the metastatic process. 
Thus, we will analyze the effect of GPR55 on 
breast cancer cell migration and invasion in vi-
tro and in tumor growth and lung colonization in 
vivo. For these studies we will use breast cancer 
cells with stably knocked-down GPR55 levels or 
transfected with the corresponding control. We 
will also study the downstream mechanisms res-
ponsible for the effects of GPR55 on the pro-me-
tastatic-related features. 
The following results are not publish yet. They are 
part of a future manuscript still in preparation. 
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The orphan receptor GPR55 confers pro-metastatic advantages on 
breast cancer cells in vitro and in vivo
C. Andradas1, E. Pérez-Gómez1, S. Blalsco-Benito1, P. Dillenburg-Pilla2, D. Megías3, M. Quintani-
lla4, JS. Gutkind2, M. Guzmán1 and C. Sánchez1.
1, Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, 
Madrid, Spain. 2, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial 
Research, National Institutes of Health, Bethesda, MD, USA. 3, Confocal Microscopy Unit, Spanish 
National Cancer Research Centre, E-28029 Madrid, Spain. 4, Instituto de Investigaciones Biomédi-
cas Alberto Sols, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, 
Madrid, Spain;
Abstract
Emerging evidence points to an important role of the orphan GPCR GPR55 on tumor generation and 
growth. Thus, we have previously demonstrated that GPR55 promotes cancer cell proliferation in vitro 
and in vivo. In these work we aimed at studying whether GPR55 participates in the control of the me-
tastatic process. We demonstrate that GPR55 drives breast cancer cell migration and invasion via Gq 
heteromeric G proteins in vitro. This effect was accompanied by the activation of MMPs and the upregu-
lation metastatis-inducing genes. Furthermore, GPR55 promotes breast cancer tumor growth and lung 
colonization in vivo. Together, our data support the involvement of GPR55 on the final and most lethal 
stage of cancer progression, and suggest that pharmacological blockade of this receptor could be a 
new strategy to manage metastatic cancer.
Introduction
Metastasis is the last step in tumor progres-
sion. While non-invasive tumors are usually be-
nign, invasive tumors are the cause of 90% of 
cancer-associated deaths (Gupta and Massagué, 
2006). Metastatic cancer cells present the abili-
ty to leave the primary tumor and colonize dis-
tal niches. To do so, cancer cells acquire several 
capabilities that allow them to detach from their 
neighboring cells and the extracellular matrix, to 
migrate to and enter the circulatory system, to 
express survival signals that allow them to travel 
across the blood stream to distant tissues and to 
colonize them generating new tumoral masses 
(Hanahan and Weinberg, 2011). The identification 
of the genes and mechanisms governing all the-
se steps, and therefore the metastatic process, 
is essential for understanding cancer progression 
biology and for the development of novel thera-
peutic tools to prevent/treat metastasis. 
The orphan receptor GPR55 has been recently 
involved in tumor generation and growth (Andra-
das et al., 2011; Pérez-Gómez et al., 2012; Piñeiro 
et al., 2011). Thus, GPR55 promotes cancer cell 
proliferation, both in vitro and in vivo, and confers 
oncogenic advantage to these tumoral cells.  In 
line with this notion, GPR55 appears correlated to 
the aggressiveness of breast, brain and pancrea-
tic human cancers (Andradas et al., 2011). 
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Indirect evidence suggests that GPR55 may 
also be involved in tumor metastasis. First, GPR55 
couples to Gα12/13 (Balenga et al., 2011; Brown et 
al., 2011; Henstridge et al., 2009; Huang et al., 
2011; Lauckner et al., 2008; Obara et al., 2011; 
Oka et al., 2010; Ryberg et al., 2007) and Gαq 
(Lauckner et al., 2008; Obara et al., 2011; Wal-
deck-Weiermair et al., 2008) heterotrimeric G pro-
teins that have been related to tumor progression 
in general and cancer cell migration and invasion 
in particular (Dorsam and Gutkind, 2007; Kelly et 
al., 2007; Kim et al., 2011; Worzfeld et al., 2008). 
In addition, GPR55 activates small Rho GTPa-
ses (Balenga et al., 2011; Henstridge et al., 2009; 
Lauckner et al., 2008; Obara et al., 2011; Oka et 
al., 2009; Ryberg et al., 2007; Whyte et al., 2009), 
proteins that regulate actin cytoskeleton organi-
zation, cell-cell adhesion and cell polarity among 
others (Kelly et al., 2007), cell functions that are 
intimately related to the capability of cells to in-
vade and migrate and, therefore, to metastasize 
(Karlsson et al., 2009). More recently, GPR55 has 
been shown to promote anchorage-independent 
growth. Thus, down-regulation of GPR55 in PDV 
skin carcinoma cells (Pérez-Gómez et al., 2012) 
and PC-3 prostate cancer cells (Piñeiro et al., 
2011), inhibited cell growth in soft agar. Moreover, 
overexpression of GPR55 in the poorly metastatic 
breast cancer cell line MCF-7 confers a migratory 
phenotype to these cells, which is enhanced by 
LPI treatment and prevented by selective down-
regulation of GPR55 (Ford et al., 2010). 
In this context, we aimed at studying in depth 
the involvement of GPR55 in cancer cell invasion 
and migration. Our results show that GPR55 en-
hances the invasion and migration properties of 
the human breast adenocarcinoma cell line MDA-
MB-231 in vitro via Gαq proteins, and promotes 
tumor growth and lung colonization in vivo. 
Materials and methods
Cell culture
MDA-MB-231 human adenocarcinoma cell 
line was supplied by ATCC-LGC. These parental 
cell line and those derived from it were maintained 
in DMEM supplemented with 10% FBS and 100 
U/mL penicillin/streptomycin, and incubated at 
37ºC and 5% CO2. 
Plasmid transfection and stable cell line gene-
ration
To generate the stably GPR55 knocked-down 
MDA-MB-231 cell line, double-stranded oligonu-
cleotides encoding short hairpin RNA (shRNA) 
against human GPR55 were inserted into the psi-
U6-EGFP vector (shGPR55) (GeneCopoeia, Roc-
kville, MD). Cells were transfected with shGPR55 
or the corresponding control (psi-U6-EGFP-unre-
lated sequence vector) with Lipofectamine 2000 
according to manufacturer’s instructions (Invitro-
gen, Barcelona, Spain). Transfected cells were 
selected with gradually increasing concentrations 
of puromycin (up to 20 μg/mL) (Sigma, St. Louis, 
MO), and the most intense GFP pool was isolated 
using a FACS Vantage sorter (Becton Dickinson, 
Madrid, Spain). 
For transient transfection, the following plas-
mids were introduced into the cells using Lipo-
fectamine 2000 as transfection reagent: 3xHA-
human recombinant GPR55 plasmid (Henstridge 
et al., 2009) or the corresponding empty vector 
(pcDNA3); pCEFL vectors containing GFP, GFP 
fused to the RGS domain of PDZ-RhoGFP (GFP-
RGS) or GFP fused to the RGS domain of GRK2 
(GFP-GRK2), all of them kindly donated by Dr. 
Gutkind (NIH, Bethesda, MD). 24 h after transfec-
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tion, cells were serum starved for invasion assays. 
Lentiviral infections
To generate MDA-MB-231-luciferase cell lines, 
cells were infected with lentiviral particles contai-
ning luciferase (kindly donated by Dr. Gutkind). 
shC and shGPR55 MDA-MB-231 cells at ~50% 
confluence were incubated with viral superna-
tants for 24 h at 37ºC in the presence of 8 μg/mL 
polybrene (hezadimethrine, Sigma). Cells were 
washed with PBS and incubated in 10% FBS-
media until use. 
Real-time quantitative PCR
RNA from cell cultures was isolated with Tri-
zol Reagent (Sigma) including a DNase digestion 
step, with the DNase I recombinant (Roche, Basel, 
Switzerland). cDNA was subsequently obtained 
with Transcriptor Reverse Transcriptase (Roche). 
Real-time quantitative PCR assays were perfor-
med using the FastStart Master Mix with Rox (Ro-
che) and probes were obtained from the Universal 
Probe Library (Roche). The primers used for hu-
man GPR55 were: sense, 5’-CATGTGTTTCTC-
CAACGTCAA-3’ and anti-sense, 5’-TGCGGA-
ATTCTTTGATGACA-3’; for human ANGPTL4: 
sense, 5’-GGAACAGCTCCTGGCAATC-3’ and 
anti-sense, 5’-GTTGACCCGGCTCACAAT-3’; for 
human MMP1: sense, 5’-GTCCTTGGGGTATC-
CGTGTA-3’ and anti-sense, 5’-ACGAATTTGCC-
GACAGAGAT-3’; and for CXCL1 sense, 5’-CTT-
CAGGAACAGCCACCAGT-3’ and anti-sense, 
5’-CATCGAAAAGATGCTGAACAGT-3’. Ampli-
fications were run in a 7900 HT-Fast Real Time 
PCR System (Applied Biosystems, Carlsbard, 
CA). Each value was adjusted by using 18S RNA 
levels as reference, amplified with multispecies 
primers sense, 5’-GCTCTAGAATTACCACAG-
TTATCCAA-3’ and anti-sense, 5’-AAATCAGTTAT-
GGTTCCTTTGGTC-3’.
Western blot analysis
Tumors and cell lines were lysed on a buffer 
containing 50 nM tris HCl, 1 mM phenylmethyl-
sulfonyl fluoride, 50mM NaF, 5 mM sodium pyro-
phosphate, 1 mM sodium orthovanadate, 0.1% 
Triton X-100, 1 μg/mL leupeptin, 1 mM EDTA, 1 
mM EGTA and 10 mM sodium β-glicerophophate 
at pH 7.5 supplemented with a protease inhibitor 
cocktail (Roche), PMSF 200 μM, microcystine 200 
μM and β-mercaptoethanol 200 μM. Lysates were 
subjected to PAGE-SDS, and proteins transferred 
onto polyvinylidene fluoride membranes. Blots 
were incubated with the following antibodies: an-
ti-HA (Roche), anti-GFP (Roche) and anti-β-actin 
(Sigma) used as leading control. Luminograms 
were obtained with the Amersham Enhanced 
Chemiluminescence Detection Kit (GE Healthca-
re).
Migration assays
Migration assays were performed in a 48-well 
Boyden chambers with polyvinyl pyrrolidone free 
polycarbonate membranes of 8 μm of pore size 
(NeuroProbe, Gaithersburg, MD) previously coa-
ted with fibronectin (10 μg/mL) for 7-8 h at 4ºC. 
Chemoattractants [LPI (Sigma) or EGF (Chemicon, 
Temecula, CA)] were added to the lower chamber 
in serum-free media. Cells were serum starved 
over night and added at a density of 15000 cells/
well into the upper chamber in serum-free media. 
After 8 h of incubation at 37ºC, cells were fixed in 
methanol. Cells on the upper surface of the mem-
branes were wiped with a cotton swab and tho-
se that underwent (i.e. in the lower surface) were 
stained with hematoxilyn and counted. 
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Invasion assays
Invasion assays were performed in BD Bio-
CoatTM MatrigelTM Invasion Chambers (BD Bios-
ciences, Bedford, MA). Matrigel inserts were 
rehydrated with serum-free media. Chemoattrac-
tants [FBS or LPI (0.5 μM)] were added into the 
wells, and serum starved cells (100000/well) were 
added into the inserts. Plates were incubated for 
24 h at 37ºC and 5% CO2. Cells were then fixed in 
4% formaldehyde, washed with PBS and stained 
with DAPI (100 ng/mL) (Roche). Images from in-
serts were captured in z-stack for 3D reconstruc-
tion with confocal microscope Leica TCS SP5. 
Images were processed with Imaris x64 7.3.1 
software.  
MMP activity assay
MMP2 (Gelatinase A) and MMP9 (Gelatinase 
B) activities were determined by gelatin zymogra-
phy. Media collected from cell cultures were run in 
PAGE-SDS gels in the presence of 0.1% gelatin. 
Gels were then washed with a 2.5% Triton X-100 
containing buffer to renaturalize and activate the 
gelatinases, and incubated overnight at 37°C in 
50 mM Tris, 150 mM NaCl, 10 mM CaCl2, 0.1% 
Triton X100 pH 7.5. Gels were then stained with 
Coomasie Blue and washed with 8% acetic acid-
20% methanol. Digested bands were quantified 
by densitometric analysis with Quantity One soft-
ware (Bio-Rad).
Animal experiments
All procedures involving animals were perfor-
med with the approval of the Complutense Uni-
versity Animal Experimentation Committee in 
compliance with the European official regulations. 
For orthothopic breast cancer assays, 2x106 cells 
in 50 μL of PBS were injected into the 4th right 
mammary-fat-pad of anesthesized 6-week old 
SCID/NOD female mice. Animals were randomly 
assigned in two groups: 10 mice were injected 
with the shC MDA-MB-231 cell line and 15 mice 
with the shGPR55 MDA-MB-231 cell line. Tumors 
were measured once a week with external caliper 
and volume was calculated as (4π/3) x (width/2)2 x 
(length/2). Mice were sacrificed 60 days after cell 
injection and lungs, intestine, pancreas, spleen, 
brain and tumors were collected.  All tissues were 
fixed in 4% formalin and tumors were divided into 
three portions: 1) fixed in 4% formalin, 2) snap-
frozen for protein extraction and 3) snap-frozen 
for RNA extraction. Samples for protein and RNA 
analysis were store at -80ºC until use.
For lung metastases analysis, 5x105 lucife-
rase-expressing cells, resuspended in 100 μL 
of PBS, were injected into the lateral tail vein of 
6-week old SCID/NOD mice (4 per group). Thir-
ty days after cell injection, animals were analyzed 
by bioluminescence imaging. Mice received an 
intraperitoneal injection of D-luciferin (Gold Biote-
chnology, St Louis, MO), and 15 min later lucife-
rase signal was captured by an IVIS 2000 system 
(Xenogen Corp, Alameda, CA). Imaging data were 
processed with Living Image software (Xenogen 
Corp) and analyzed using the average radiance 
(p/s/cm2/sr) of the regions of interest (ROI). Ani-
mals were sacrificed and lungs were snap-frozen 
and store at -80ºC until use. 
Statistical analysis
Statistical analysis ANOVA with a post-hoc 
analysis by the Student–Newman–Keuls’ test was 
routinely used. Unless otherwise stated, data are 
expressed as mean±s.e.m.
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Results and discussion 
GPR55 promotes breast cancer cell migration 
To analyze the role of GPR55 on the metastatic 
potential of cancer cells, we first studied whether 
this receptor modulates the migration properties 
of the highly metastatic breast cancer cell line 
MDA-MB-231.  We performed in vitro migration 
assays in Boyden chambers using LPI, a poten-
tial GPR55 endogenous ligand, as chemoattrac-
tant. MDA-MB-231 cells, which express elevated 
levels of GPR55 (Andradas et al., 2011; Ford et 
al., 2010), migrated towards LPI in a dose-depen-
dent manner, following a Gaussian pattern, being 
0.5 μM LPI the most efficient chemoattractant 
concentration (figure 1A). Stably knock-down of 
GPR55 by selective shRNA (figure 1B) signifi-
cantly impaired migration towards LPI (figure 1A). 
GPR55 knock-down did not affect the migration 
response towards epidermal growth factor (EGF), 
a ligand that binds to the tyrosine kinase recep-
tor EGFR (figure 1A). These results indicate that 
GPR55 promotes the migration of breast cancer 
cells.
GPR55 enhances the invasiveness of breast 
cancer cells
We next analyzed whether GPR55 regula-
tes the invasive capacity of breast cancer cells, 
another feature that is intimately related to their 
metastatic potential. In this case, we carried out 
invasion assays in matrigel Boyden chambers. 
MDA-MB-231 cells showed an invasive respon-
se towards both FBS and LPI (figure 2A and 
2B). This effect was significantly reduced when 
GPR55 was stably knocked-down (figure 2A and 
2B). Moreover, when GPR55 expression was re-
constituted (figure 2C) tumor cells increased their 
invasiveness towards FBS and LPI (figure 2D and 
2E).These data support that GPR55 promotes the 
invasion of breast cancer cells.
GPR55 signals breast cancer cell invasion 
through Gq proteins 
It has been described that GPR55 couples 
to G12/13 and Gq (Henstridge et al., 2011; Ross, 
2009). Both classes of heterotrimeric G proteins 
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have been implicated in tumor progression and 
metastasis (Dorsam and Gutkind, 2007; Kelly et 
al., 2007). Consequently, we next examined whe-
ther the GPR55-induced enhancement of cancer 
cell invasion was mediated by coupling of the re-
ceptor to either G12/13 or Gq. We used two chimeric 
constructions that behave as dominant negative 
mutants for G12/13 and Gq. These constructs con-
sist of the green fluorescent protein (GFP) fused 
either to the RGS domain of PDZ-RhoGEF, that 
binds to and impairs activation of G12/13, or to the 
RGS domain of GRK2 that binds to Gq blocking 
its signaling pathway. Cells were transfected with 
either construct (figure 3A) and invasion assays 
were performed. Blocking of G12/13 signaling with 
the GFP-RGS chimera did not affect the enhan-
ced invasion towards FBS or LPI produced by 
GPR55 overexpression (figure 3B and 3C). In 
contrast, impairement of Gq signaling with the 
GFP-GRK2 construction blocked the increase in 
the invasive potential of cancer cells induced by 
GPR55 overexpression (figure 3D and 3E). These 
data indicates that GPR55 enhances breast can-
cer cell invasion via Gq signaling.
GPR55 downregulation reduces MMP2 and 
MMP9 activity
Extracellular matrix remodeling is crucial du-
ring cancer progression. This process is carried 
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out by different proteinases, being matrix meta-
lloproteinases (MMPs) one of the most represen-
tative members. MMPs present proteolytic activi-
ty that degrades physical barriers during cancer 
progression, at the local site where tumors are 
primarily originated during the intravasation and 
extravasation processes, and at the distant or-
gans where metastases are generated (Gialeli et 
al., 2010; Hua et al., 2011). Since tumor invasion 
and metastasis are often associated with enhan-
ced activity of MMP2 and MMP9, we examined 
whether GPR55 modulates the activity of these 
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tow MMPs. By using gelatin zymogram assays 
with media from MDA-MB-231 cells, we obser-
ved that MMP2 and MMP9 activities were signifi-
cantly reduced when GPR55 expression was sta-
bly knocked-down (figure 4). These data suggest 
that the invasive phenotype associated to eleva-
ted levels of GPR55 may be due, at least in part, 
to enhanced MMP2 and MMP9 activities.
GPR55 promotes tumor growth and invasion 
in vivo 
We finally analyzed whether GPR55 modulates 
breast cancer progression in vivo. First, orthoto-
pic breast tumors were generated by injection 
of MDA-MB-231-derived cell lines into the ma-
mmary fat pad of NOD/SCID mice. As show in 
figure 5, stable downregulation of GPR55 signi-
ficantly reduced tumor growth (figure 5A). Next, 
we analyzed the involvement of GPR55 in two 
steps of the metastatic process closely connec-
ted to the invasive potential of cancer cells: the 
extravasation and colonization of distant tissues. 
MDA-MB-231 derived luciferase-expressing cell 
lines were injected in the tail vein of immunede-
ficient mice and lung metastases were evaluated 
30 days after cell injection. Although, due to the 
reduced number of animals per group, no signifi-
cant differences were observed, animals injected 
with 231 shC cells tended to present higher lung 
metastasis than those injected with GPR55 knoc-
ked down cells (figure 5B and 5C).
Different studies have determined that the in-
duction of specific genes determines the capacity 
of breast cancer cells to generate metastasis spe-
cifically in the lungs. Some of them are matrix me-
talloproteinase 1 (MMP1), chemokine CXCL1 and 
angiopoetin-like 4 (ANGPTL4) (Minn et al., 2005; 
Padua et al., 2008). We analyzed by real-time 
quantitative PCR, the expression of these genes 
in the metastatic lungs generated in our tail vein 
injection-experiments. The mRNA expression of 
these three markers was significantly reduced in 
metastases generated from GPR55 stably knoc-
ked-down cells (figure 5D). 
Together, these results indicate that GPR55 
promotes tumor progression in vivo, by conferring 
a more metastatic phenotype to breast cancer 
cells. 
Metastasis is the principal cause of cancer-
associated deaths, and is produced by a lethal 
combination of intrinsic properties of the tumor 
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cells and signals coming from the tumor mi-
croenvironment and from different organs of the 
body (Ben-Baruch, 2007; Nguyen and Massagué, 
2007). Here we show that the LPI/GPR55 system 
contributes to breast cancer progression. On one 
hand, GPR55 expression confers pro-metastatic 
advantages on cancer cell directly by enhancing 
their migration and invasion capabilities. In addi-
tion, we show that LPi behaves as a chemoattrac-
tant on GPR55 expressing cells, suggesting that 
it may contribute to the communication between 
tumor cells and the environment. This hypothesis 
is supported by the fact that  increased circula-
ting levels of LPI from ovarian cancer patients are 
associated with late-stage cancers or recurrence 
(Sutphen et al., 2004; Xiao et al., 2000). Similar 
associations have been found for other lysophos-
pholipids. For example, modulation of systemic 
S1P, either by inhibiting its synthesis or by bloc-
king S1P with a specific monoclonal antibody, re-
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duced prostate cancer growth and lung metasta-
sis generation (Ponnusamy et al., 2012).
 
Our results show that GPR55-induced actions 
on breast cancer cell invasion are mediated by Gq 
heterotrimeric G proteins. However, the specific 
downstream effectors regulating the invasive and 
migratory phenotype are still unknown. Elucida-
ting these effectors and the associated signaling 
pathways may facilitate the pharmacological mo-
dulation of GPR55-driven cancer progression. 
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CHAPTER 4
Recent reports have described that GPR55 can be 
activated by different cannabinoid compounds. In 
addition, it is well established that cannabinoids 
control cell proliferation. Thus, in this last chapter 
we will study whether GPR55 mediates the effects 
of THC on cancer cell proliferation. First, we will 
analyze the consequence of modulating GPR55 
expression on THC action. Then, we will try to un-
ravel how THC produces such effects via GPR55. 
In particular, we will study whether THC promotes 
a release of intracellular calcium via GPR55 and 
whether THC action is produced by functional in-
teraction of GPR55 with classical cannabinoid re-
ceptors.
The following results are not publish yet. They are 
part of a future manuscript still in preparation. 
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Introduction
During the last decades, different findings 
have made possible the characterization of a no-
vel cellular communication network named as the 
“endocannabinoid system” (ECS). This system 
consists of different membrane receptors, mainly 
CB1 and CB2, their specific endogenous ligands, 
known as endocannabinoids, and the enzymes 
involved in their synthesis and degradation (Licht-
man et al., 2010). The ECS controls a wide variety 
of biological functions such as pain, motor coor-
dination or appetite among other functions.
 
A family of compounds synthesized by the 
plant Cannabis sativa (marijuana) has the ability to 
activate this system. The main representative of 
this family, due to its abundance in the plant and its 
psychotropic potency is Δ9-tetrahydrocannabinol 
(THC) (Mechoulam and Gaoni, 1967). THC, by 
binding to the same cannabinoid receptors than 
endocannabinoids, exert a variety of effects such 
as analgesia, appetite stimulation or neuropro-
tection, just to name a few. In the last 15 years, 
evidence has accumulated demonstrating that 
endogenously-produced, plant-derived and syn-
thetic cannabinoids exert antitumoral responses. 
Specifically, cannabinoids present anti-proliferati-
ve, pro-apoptotic, anti-angiogenic and anti-inva-
sive properties both in vitro and in animal models 
of cancer (Guzmán, 2003; Velasco et al., 2012).
Abstract
GPR55 is an orphan G protein-coupled receptor that has been proposed to be engaged and activated 
by lysophospholipids (specifically by L-α-lysophosphatidylinositol) and cannabinoids (the active com-
ponents of marijuana and their derivatives). It is well established that cannabinoids control cancer cell 
proliferation. Thus, these compounds generally induce a biphasic effect: while low concentrations of 
cannabinoids induce cancer cell proliferation, high concentrations exert the widely reported anti-prolife-
rative action. In this work we aimed at studing the potential participation of GPR55 in the effect of THC 
on cancer cell proliferation. We show that GPR55 mediates the induction of cell proliferation by low con-
centrations of THC in different cancer cell types. Moreover, we describe a functional interaction between 
GPR55 and the classical cannabinoid receptor CB1. Our data suggest that different GPR55/CB1 interac-
tion statuses may provide a mechanistic expanation for the biphasic effects of THC on cell proliferation.
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Cannabinoids exert most of their effects by 
binding to and activating CB1 and CB2, two can-
nabinoid-specific GPCRs (Pertwee et al., 2010). 
However, different evidences suggest the existen-
ce of other non-CB1/CB2 cannabinoid receptors, 
at least in neurons, vascular and immune cells 
(Kreitzer and Stella, 2009). The orphan receptor 
GPR55 has been recently proposed to be enga-
ged and activated by certain cannabinoids (Ross, 
2009), and some authors propose that it can be 
considered the third cannabinoid receptor (Baker 
et al., 2006). However, the controversial pharma-
cology reported so far for this receptor does not 
unequivocally support this notion (Ross, 2009; 
Sharir and Abood, 2010). Independently of whe-
ther GPR55 does or does not belong to the can-
nabinoid receptor family, its involvement in cancer 
physio-pathology has been clearly demonstrated. 
Thus, GPR55 promotes cancer cell proliferation 
(Andradas et al., 2011; Piñeiro et al., 2011), migra-
tion and invasion in vitro (Ford et al., 2010) (chap-
ter 3 of this Thesis). Moreover, GPR55 induces 
tumor growth and promotion in vivo (Andradas 
et al., 2011; Pérez-Gómez et al., 2012) (chapter 
3 of this Thesis). Considering that GPR55 has an 
important role in cancer and that this receptor is 
engaged by some cannabinoids, we aimed at in-
vestigating its potential involvement in the effect 
of THC on the proliferation of cancer cells. 
It has been described that cannabinoids exert 
dose-dependent biphasic effects. For example, 
they can be both anorexigenic or orexigenic, 
anxiolytic or anxiogenic, and analgesic or algesic 
depending on the administrated dose (Sulcova 
et al., 1998). Similar biphasic effects have been 
described on the proliferation of certain cancer 
cells. Thus, while “high” concentrations of can-
nabinoids exert the well known anti-proliferative 
actions, “low” concentrations have the opposite 
effect, increasing cancer cell proliferation rates 
(Caffarel et al., 2010) (unpublished data from our 
laboratory). Here, we show that GPR55 mediates 
the stimulatory effect of THC on cell proliferation 
via GPR55/CB1 functional interaction.
Materials and Methods
Cell cultures and viability assays
T98G human glioblastoma and EVSA-T human 
breast adenocarcinoma cell lines were supplied 
by ATCC-LGC and HEK293 cells were kindly pro-
vided by Dr. Maria Waldhoer (Medical University of 
Graz, Austria). T98G and HEK293 cell lines were 
maintained in DMEM supplemented with 10% 
FBS and 1U/mL penicillin/streptomycin. EVSA-T 
cell line was maintained in RPMI supplemented 
with 10% fetal bovine serum (FBS) and 100 U/mL 
penicillin/streptomycin. All cells were incubated at 
37ºC and 5% CO2. 
Before cannabinoid challenge, cells were 
transferred to a low (0.5%) FBS-containing me-
dia overnight and then treated with THC (THC, 
The Health Concept) or the corresponding vehicle 
(DMSO) for 36 h. Cell viability was determined by 
the MTT (3-4,5-dimethylthiazol-2,5-diphenyltetra-
zolium bromide thiazol blue) test (Sigma, St. Lo-
uis, MO) according to manufacturer’s instructions. 
Plasmids and transfections
Cells were transfected with a 3xHA-human 
recombinant GPR55 plasmid (Henstridge et al., 
2009), with a Gα16 vector (kindly provided by Dr. 
Maria Waldhoer) or with the corresponding empty 
vector (pcDNA3). Lipofectamine 2000 (Invitrogen, 
Barcelona, Spain) was used as transfection rea-
gent according to manufacturer’s instructions. 24 
94
h after transfection, cells were seeded at a density 
of 5000 cells/cm2 for viability assays or prepared 
for calcium assays. 
Genetic knock-down of GPR55 by small inter-
fering RNA (siRNA)
Cells were transfected with specific siRNA 
duplexes using DharmaFECT 3 as transfection 
reagent according to manufacturer’s instructions 
(Dharmacon-Thermo Scientific, Lafayette, CO). 
siRNA for human GPR55 was a SMARTpool from 
Dharmacon-Thermo Scientific. The sequences 
were 5’-GAAUUCCGCAUGAACAUCAUU-3’, 
5’-GAGAAACAGCUUUAUCGUAUU-3’, 5’-AA-
GAACAGGUGGCCCGAUUUU-3’ and 5’-GCUA-
CUACUUUGUCAUCAAUU-3’. The non-targeted 
control sequence was 5’-UUCUCCGAACGUGU-
CACGUtt-3’, from Applied Biosystems-Ambion 
(Austin, TX).
Real-time quantitative PCR
RNA from cell cultures was isolated with Trizol 
Reagent (Sigma, St. Louis, MO) including a DNa-
se digestion step, with the recombinant DNase 
I (Roche, Basel, Switzerland). cDNA was subse-
quently obtained with Transcriptor Reverse Trans-
criptase (Roche). Real-time quantitative PCR was 
performed using the FastStart Master Mix with 
Rox (Roche) and probes were obtained from the 
Universal Probe Library (Roche). The primers for 
human GPR55 were: sense, 5′- CATGTGTTTCTC-
CAACGTCAA-3 and anti-sense, 5′-TGCGGA-
ATTCTTTGATGACA-3′. Amplifications were run in 
a 7900 HT-Fast Real Time PCR System (Applied 
Biosystems, Carlsbard, CA). 18S RNA was 
used as reference (multispecies primers: sense, 
5′-GCTCTAGAATTACCACAGTTATCCAA-3′, anti-
sense, 5′-AAATCAGTTATGGTTCCTTTGGTC-3′).
Calcium assays
Intracellular calcium release was measured by 
monitoring the fluorescent intensity of a calcium 
sensitive dye after calcium binding (FLIPR Cal-
cium 4 Assay Kit, Molecular Devices, Sunnyva-
le, CA). 24 h after cells transfection (see above), 
cells were seeded in 96-well black bottom-clear 
plates, coated with 1% poly-D-lysine (Sigma) in 
10% FBS-containing media at a density of 40000 
cells/well.  Before the calcium assay, cells were 
starved overnight. Cells were then incubated in 
dye buffer for 1 h at 37ºC. Ca2+ mobilization was 
measured immediately after agonist application 
(L-α-lysophosphatidylinositol (LPI) (Sigma), THC, 
2-arachidonoylglycerol (2-AG) (Tocris Bioscience, 
Ellisville, MO), CP-55940 (Tocris Bioscience) and 
DMSO) and recorded for 2 min in a FlexStationII 
System (Molecular Devices). Maximum minus mi-
nimum peak height was used to calculate calcium 
response. 
Statistical analysis
Statistical analysis  ANOVA with a post-hoc 
analysis by the Student–Newman–Keuls’ test was 
routinely used. Unless otherwise stated, data are 
expressed as mean±s.e.m.
Results and discussion
GPR55 modulates the THC-induce pro-prolife-
rative peak
To analyze whether GPR55 participates in the 
effect of THC on cancer cell proliferation we se-
lectively knocked-down GPR55 in human T98 
glioblastoma cells by small interference RNA 
(siRNA). First, we observed that THC induced a 
Results and Discussion
95
biphasic response on cancer cell viability. Thus, 
low-concentrations (up to 2 μM) enhanced pro-
liferation of T98 cells, while high concentrations 
(above 2 μM) produced a significant decrease in 
cell viability. Interestingly, GPR55 down-regula-
tion blocked the proliferative peak induced by low 
concentrations of THC, and did not modify the 
anti-proliferative effect produced by higher con-
centrations (figure 1A). To determine if this was 
a glioblastoma-specific response, we performed 
similar experiments in the human breast adeno-
carcinoma cell line EVSA-T. As in T98 cells, THC 
induced a bell-shaped response in breast cancer 
cell viability (stimulation at low concentrations and 
inhibition at high concentrations) and the prolife-
rative effect was prevented by selective GPR55 
knock-down (figure 1B). To further confirm the in-
volvement of GPR55 in THC-induced stimulation 
of proliferation, we overexpressed the receptor 
and challenged the cells with different concen-
trations of THC. GPR55 overexpression resulted 
in an increased pro-proliferative response to low 
concentrations of THC, both in glioblastoma (fi-
gure 2A) and breast cancer cells (figure 2B). To-
gether, these data strongly suggest that GPR55 
mediates the proliferation inducing effect of THC. 
THC does not mobilized intracellular calcium 
via GPR55
We next aimed at determining if THC action 
was produced by direct activation of GPR55. 
Whether THC is able to activate GPR55 is still 
a controversial issue (Sharir and Abood, 2010). 
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Figure 1. GPR55 knock-down prevents the pro-proliferative response induced by low concentrations of THC. 
Cell viability of human glioblastoma T98 (A) and human breast adenocarcinoma (B) cells in response to increasing 
concentrations of THC. Red lines correspond to cells knocked-down for GPR55 expression (GPR55 siRNA) and blue 
lines to cells transfected with a control siRNA (C siRNA). Right panels represent the relative GPR55 mRNA levels, as 
determined by real-time quantitative PCR, after GPR55 silencing. *p<0.05; **p<0.01 vs C siRNA cells. 
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Figure 2. GPR55 overexpression enhances the pro-proliferative response induced by low concentrations of THC. 
Cell viability of human glioblastoma T98 (A) and human breast adenocarcinoma (B) cells in response to increasing con-
centrations of THC. Orange lines correspond to cells that overexpress GPR55 (hGPR55) and blue lines to cells transfected 
with the control plasmid pcDNA3. Right panels represent the relative GPR55 mRNA levels, as determined by real-time 
quantitative PCR, after GPR55 overexpression. *p<0.05; **p<0.01 vs pcDNA3 cells. 
Some authors have reported agonistic properties 
of THC on GPR55 (Lauckner et al., 2008; Ryberg 
et al., 2007; Yin et al., 2009) while others repor-
ted no action of the cannabinoid on this recep-
tor (Kapur et al., 2009; Oka et al., 2010; 2007). To 
find out what the situation was in our system we 
used intracellular calcium release as a readout of 
receptor activation. Since T98 and EVSA-T cells 
express other receptors that can be activated by 
THC (CB1 and CB2), we performed these expe-
riments in HEK293 cells (which do not express 
these receptors). First, we confirmed that ectopic 
overexpression of GPR55 in these cells induced 
a proliferative effect in response to THC (figure 
3A). The proposed GPR55 endogenous ligand 
LPI induced a significant increase in intracellular 
Ca2+ levels in HEK-GPR55 cells (figure 3B). On 
the contrary, neither THC or other CB1/CB2 mixed 
agonists (CP-55940 and 2-AG) produced any de-
tectable alteration on intracellular Ca2+ (figure 3B). 
These compounds, however, were able to enhan-
ce intracellular Ca2+ levels in HEK cells stably ove-
rexpressing one of their well-established targets, 
the CB1 receptor, which, as expected, did not res-
pond to LPI (figure 3C). 
GPR55-CB1 functional interaction modulates 
proliferation in response to THC
Since GPR55 clearly mediates THC proliferati-
ve action, and the best established targets of this 
cannabinoid are CB1 and CB2 receptors, we next 
aimed at elucidating if there is a functional cross-
talk between GPR55 and classical cannabinoid 
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receptors. It has been previously described that 
receptor interaction modulates the response and 
function of the individual receptors (Vischer et al., 
2011). In particular, it has been shown that CB1 
can form heteromers with other receptors like the 
D2-dopamine receptor or the μ-opioid receptor 
(Pertwee et al., 2010). In addition, a recent report 
suggests that CB1 and CB2, can form heteromers 
(Callen et al., 2012). Moreover, an interaction bet-
ween GPR55 and CB1 (Kargl et al., 2012) and CB2 
(Balenga et al., 2011) has been described. In all 
these cases, the association between receptors 
modulated each receptor’s activity. Callen and 
coworkers reported the presence of CB1/CB2 he-
teromers in the brain that, when activated simulta-
neously, blocked the activation of the Akt pathway 
and the neurite outgrowth induced by activation of 
each receptor independently (Callen et al., 2012). 
A functional interaction between GPR55 and CB2 
has been described in neutrophils (Balenga et al., 
2011). GPR55 activation enhances neutrophil mi-
gratory response towards the CB2 agonist 2-AG, 
and inhibits neutrophil degranulation and ROS 
production induced by CB2 (Balenga et al., 2011). 
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Figure 3. THC does not produce calcium release via GPR55. A, Viability of HEK293 cells stably overexpressing GPR55 
(HEKGPR55) or the corresponding empty vector (HEK) after 36 h of incubation with the indicated concentration of THC. 
*p<0.05;**p<0.01 vs HEK cells. B, Intracellular calcium levels detected in HEK-GPR55 (B) and HEK-CB1 (C) cells after 
treatment with increasing concentration of LPI, THC, CP-55940, 2-AG or the corresponding vehicle (DMSO). Results are 
expressed as relative fluorescence units (RFU). For experiments with HEK-CB1 cells, since CB1 is mainly coupled to Gai 
proteins, which do not mobilize intracellular calcium, cells were previously transfected with Ga16, a promiscuous member 
of the Gaq/11 family that can bind to most GPCRs, inducing the activation of PLCb and subsequent Ca
2+ release (Kostenis 
et al., 2005). 
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Figure 4. GPR55 and CB1 present a negative cross talk 
on THC-induced cell proliferation. Viability of HEK293 
cells stably overexpressing CB1 (HEKCB1) (A) CB1 and 
GPR55 (HEKGPR55-CB1) (B) or the corresponding empty 
vector (HEK) (A and B) in response to 36 h challenge with 
the indicated concentrations of THC. **p<0.01 vs HEK293 
cells. 
Kargl and coworkers showed that the presence 
of CB1 inhibits activation of NFAT, SRE and ERK 
via GPR55. On the other hand, the presence of 
GPR55 enhanced the activation of ERK and NFAT 
mediated by CB1 (Kargl et al., 2012).
To analyze whether GPR55 functionally inte-
racts with cannabinoid receptors in our context 
and, if so, if this interaction is relevant in the res-
ponse to THC, we performed cell viability experi-
ments in HEK293 cells stably expressing GPR55, 
CB1 or GPR55 and CB1. As described before, ove-
rexpression of GPR55 enhanced the proliferation 
induced by THC (figure 3A). The same effect was 
observed when CB1 was overexpressed (figure 
4A). Interestingly, simultaneous overexpression 
of both receptors abolished the proliferative peak 
induced by THC (figure 4B). These data indicate 
that CB1 and GPR55 functionally interact to con-
trol cell proliferation upon THC treatment, and su-
ggest that CB1/GPR55 interaction status may be 
the molecular explanation underlying the biphasic 
effect of THC on cancer cell proliferation. Further 
experiments will be performed to confirm this 
hypothesis and to determine, for example, what 
are the specific signaling pathways activated by 
GPR55, CB1 and GPR55/CB1 in the pro- and anti-
proliferative action of THC; if the functional inte-
raction is the consequence of a physical contact 
between receptors or to a downstream signaling 
crosstalk; what is the contribution of other well-
established targets of THC (mainly CB2), etc.
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G protein-coupled receptors (GPCRs) repre-
sent the largest superfamily of cellular recep-
tors. They control a whole range of physiological 
functions, and their deregulation contributes to 
many human diseases. Although they represent 
together with enzymes the most common phar-
macological target of currently prescribed drugs, 
to date only a small percentage of GPCRs are 
being therapeutically exploited in cancer. Well 
characterized GPCRs as well as orphan recep-
tors have been linked to cancer initiation and pro-
gression (Dorsam and Gutkind, 2007; Lappano 
and Maggiolini, 2011). Elucidating their specific 
mechanism of action and identifying additional 
GPCRs involved in cancer development is the-
refore a reasonable strategy to fight against this 
pathology. Results from this Thesis reveal that the 
orphan GPCR GPR55 plays an important role in 
cancer physio-patology. Specifically, we demons-
trate that GPR55 promotes tumor generation and 
progression by conferring proliferation, migration 
and invasion advantages on cancer cells (Dis-
cussion figure 1). Together, these results point to 
GPR55 as a new potential target in oncology as 
well as a potential biomarker associated to poor 
prognosis. 
GPR55 is expressed in tumor cells
First of all, by analyzing human cell lines and 
tumor biopsies from patients, we show that 
GPR55 is expressed in a wide variety of human 
cancers. Moreover, the expression of the receptor 
was significantly increased in tumoral tissues as 
compared with healthy tissues, and in highly ag-
gressive vs poorly aggressive tumors. These data 
indicate that GPR55 expression may be used as a 
potential biomarker in cancer with prognostic va-
lue. Aberrant GPCR expression associated to tu-
mor progression has been previously described in 
human cancers, which promotes tumor progres-
sion (Dorsam and Gutkind, 2007; Li et al., 2005; 
Wu et al., 2012). For example, the receptors for 
the lysophospholipids LPA and S1P are overex-
pressed in tumors from different origins such as 
breast, gastric, thyroid or ovarian cancers (Murph 
et al., 2006; Murph and Mills, 2007). In addition, 
cannabinoid receptors, also activated by lipidic 
compounds, are upregulated in many tumors 
such as lymphomas, hepatocellular carcinomas, 
pancreatic adenocarcinomas and breast cancers 
among others (Caffarel et al., 2012; Malfitano et 
al., 2011). These evidences point to the existence 
of a lipid-evoked control of cancer physiopatho-
logy. According to this idea, LPI/GPR55 could be 
a component of this oncogenic lipid circuitry in 
cancer progression. To confirm the relevance of 
GPR55 as a prognostic biomarker, the expres-
sion of the receptor should be characterized in 
a greater number of human tumor samples. We 
are currently studying the expression of GPR55 in 
a large battery of human breast cancer biopsies 
from primary tumors as well as from the metas-
tatic lesions. Complete clinical information about 
these samples (hormone and HER-2 receptor sta-
tus, histological grade, patient disease-free and 
overall survival, etc.) is available, and therefore we 
expect to be able to establish associations bet-
ween GPR55 expression and patient prognosis in 
the next future. 
GPR55 promotes cancer cell proliferation
We found that GPR55 confers a proliferative 
advantage on cancer cells from different origins, 
including gliomas, breast adenocarcinoma and 
squamous skin cell carcinoma, both in vitro and 
in vivo. Additional results obtained by Piñeiro and 
coworkers and by our group confirmed these ob-
servations in vitro in prostate, ovarian (Piñeiro et 
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al., 2011) and pancreatic cancer cells (our groups 
unpublished results), which suggests that the en-
hanced proliferation induced by GPR55 is general 
rather than cell-type specific. 
It is important to point out that the effects on 
cell proliferation described here relied upon mo-
dulation of the levels of GPR55, without applica-
tion of any ligand. The enhancement in cancer 
cell proliferation could be explained either by 
ligand-independent constitutive activation of the 
receptor or by the production of GPR55 ligands 
by tumor cells. Although constitutive activation of 
GPR55 in cancer cells cannot be ruled out, our 
data and the data obtained by other groups sug-
gest that cancer cells are exposed to an endoge-
nous tone of the putative GPR55 ligand LPI. Thus, 
it has been shown that fibroblasts and epithelial 
cells generate mitogenic LPI upon Ras induced 
transformation (Falasca and Corda, 1994; Falasca 
et al., 1998). In addition, either pharmacological 
(this Thesis) or genetic (Piñeiro et al., 2011) bloc-
kade of the main enzyme responsible for LPI syn-
thesis (cytosolic phospholipase A2 (cPLA2)) inhi-
bited the effects of GPR55 on cell proliferation. 
Moreover, high levels of LPI have been detected 
in ascites and plasma from patients with ovarian 
cancer compared with healthy controls (Sutphen 
et al., 2004; Xiao et al., 2001). Interestingly, the 
most potent LPI species in terms of activation of 
GPR55, arachidonoyl-LPI (Oka et al., 2009), is the 
most increased LPI species in these patients (Su-
tphen et al., 2004). Together, these results sug-
gest that the release of LPI from cancer cells may 
be a strategy to stimulate cancer cell proliferation. 
Similarly, the lysophospholipids LPA (Sutphen et 
al., 2004; Xiao et al., 2001) and S1P (Hong et al., 
1999) are frequently elevated in cancer patients. 
Discussion figure 1. Role of GPR55 in cancer development. GPR55 is expressed by tumor cells and promotes cancer 
cell proliferation by activation of the ERK/MEPK cascade, cancer cell invasion via Gq, migration and metastasis in vivo by 
activating MMP2 and MMP9 and by increasing the levels of other metastatic markers. In addition, GPR55 promotes tumor 
immune infiltration by upregulating pro-inflammatory cytokines. 
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These lysophospholipids are potent mitogenic 
factors that, by activating their cognate recep-
tors (LPA and S1P receptors), stimulate cancer 
cell proliferation, among other functions, thereby 
promoting tumor progression (Dorsam and Gut-
kind, 2007; Lin et al., 2010; Pyne and Pyne, 2010). 
Once again, these data collectively suggest that 
LPI/GPR55 are part of a complex lipidic system 
that controls cell proliferation and is altered in 
cancer.
Results obtained from the chemically-induced 
skin carcinogenesis model show that GPR55 ex-
pression is predominantly associated to the basal 
layer of the epidermis, which is a highly prolife-
rating poorly-differentiated compartment of the 
skin. Preliminary data from our group suggest a si-
milar expression pattern in breast cancer. Normal 
breast is formed by lobules and ducts, a structure 
made of two cell layers: one in contact with the 
light of the lobules and ducts, made of luminal 
epithelial cells, and one made of myoepithelial 
cells, juxtaposed to the basal membrane (Rakha 
et al., 2008). Recent molecular studies have esta-
blished a strong association between aggressive-
ness and the basal-like genotype (Bertucci et al., 
2012; Rakha et al., 2008) (see below). Interestin-
gly, we have observed higher GPR55 expression 
in basal-like (MDA-MB-231 and MDA-MB-468) 
than in luminal-like breast cancer cell lines (Ford 
et al., 2010) (Discussion figure 2). Moreover, preli-
minary data from our group show that, as in skin 
cancer, GPR55 expression is mostly associated 
to this basal, highly proliferative and poorly diffe-
rentiated compartment.
It has been described that GPR55 activates 
the ERK/MAPK cascade in different cell systems, 
including HEK293 cells (Anavi-Goffer et al., 2011; 
Henstridge et al., 2010; Kargl et al., 2012; Oka et 
al., 2009; 2007), osteoclasts (Whyte et al., 2009), 
endothelial cells (Zhang et al., 2010), U2OS cells 
(Kapur et al., 2009; Kotsikorou et al., 2011) and 
the pheocromocytoma cell line PC12 (Obara et 
al., 2011). The ERK/MAKP cascade is one of the 
main regulators of cell proliferation (McCubrey et 
al., 2007). Results described in this Thesis show 
a link between GPR55 and ERK on cell prolifera-
tion. Thus, GPR55 expression is associated with 
active ERK and the subsequent increase of the 
transcription factor c-Fos, and cyclin D1 in vitro 
and in vivo. Furthermore, Piñeiro and co-workers 
have also reported that GPR55 controls ERK acti-
vity (Piñeiro et al., 2011). The authors observed a 
clear ERK activation after LPI stimulation in pros-
tate and ovarian cancer cells, an effect that was 
blocked after down-regulation or pharmacological 
inhibition of GPR55 (Piñeiro et al., 2011). Although 
these results support that GPR55 controls cell 
proliferation through the ERK/MAPK cascade, the 
involvement of other players cannot be ruled out. 
For example, the pro-tumorigenic PI3K/Akt sig-
naling pathway, which is over-activated in many 
cancers (Vivanco and Sawyers, 2002), has been 
implicated in GPR55 action on cancer cell proli-
feration. Thus, Piñeiro and co-workers observed 
that activation of GPR55 induces phosphorylation 
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Discussion figure 2. GPR55 expression is increased in 
basal-like breast cancer cell lines. Analysis of GPR55 
expression by real-time quantitative PCR in five breast 
cancer cell lines: two basal-like cancer cell lines MDA-
MB-231 and MDA-MB-468, and three luminal cell lines 
MCF-7, BT474, SKBr3.
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of Akt and that GPR55 knock-down decreased 
the basal levels of activated Akt (Piñeiro et al., 
2011). 
GPR55 drives breast cancer cell invasion 
via Gq
The potential of cancer cells to disseminate 
throughout the body and generate metastases is 
one of the main determinants of cancer aggressi-
veness and patients’ overall survival. As descri-
bed in the Introduction, GPR55 couples to G12/13 
and Gq proteins (Henstridge et al., 2011; Ross, 
2009), heterotrimeric proteins that are involved 
in cancer invasion and metastasis (Dorsam and 
Gutkind, 2007). It has also been described that 
activation of GPR55 stimulates small Rho GTPa-
ses (Henstridge et al., 2011), proteins that modu-
late cytoskeleton organization, motility and cell 
adhesion, among other functions (Karlsson et al., 
2009). These observations suggest a potential 
role of GPR55 in invasion and metastasis. Results 
presented in this Thesis confirm that GPR55 pro-
motes cancer cell invasion and migration in vitro 
and in vivo. This idea was strengthen by Falasca’s 
and Ross’ groups. Thus, GPR55 down-regulation 
in prostate cancer cells reduced the number of 
colonies formed in soft agar, and the colonies 
that grew were less organized than those formed 
by GPR55-expressing cells (Piñeiro et al., 2011). 
Additionally, overexpression of GPR55 in the 
poorly metastatic breast cancer cell line MCF-7 
induced migration in cell culture, and activation 
with LPI enhanced the migration of the GPR55-
overexpressing cells towards serum (Ford et al., 
2010). 
The mechanisms underlying the pro-invasive 
potential of GPR55 are still poorly understood. 
In this Thesis, we demonstrate that the invasion 
induced by GPR55 in MDA-MB-231 breast can-
cer cells is mediated by Gq proteins. Our results 
suggest that activation of MMPs is also involved 
in the GPR55 effect on cancer cell invasion and/
or migration. MMPs promote tumor angiogenesis, 
invasion and metastasis by inducing the degra-
dation of the extracellular matrix, the disruption 
of cell-cell interactions, the release of angiogenic 
factors and the processing of membrane-asso-
ciated growth factors and cytokines (Gialeli et al., 
2010; Hua et al., 2011). In fact, tumors tissues, 
plasma, serum and urine from patients with diffe-
rent cancers, such as breast cancer, pancreatic 
cancer, lung cancer, colorectal cancer, bladder 
cancer and ovarian cancer, present elevated le-
vels of MMPs (Roy et al., 2009). We found that 
the activity of MMP2 and MMP9, two MMPs often 
enhanced in cancer, was significantly reduced in 
GPR55 knocked-down cells. Interestingly, it has 
been reported that the lysophospholipids LPA 
and S1P increase cancer cell invasion (Murph et 
al., 2006; Panupinthu et al., 2010) by, at least par-
tially, activating MMPs (Kim et al., 2011; Komachi 
et al., 2012). Further experiments should be per-
formed to widen our knowledge on the molecular 
mechanisms underlying the pro-invasive and pro-
migratory actions of GPR55.
Most primary tumors display organ selectivity 
for the generation of metastases. As described in 
the Introduction, GPCRs can participate in this 
selectivity. The metastatic organ releases specific 
GPCR ligands, which serve as chemoattractant 
signals for cancer cells that express those GPCRs 
located in the primary tumors or in the circulation. 
Our results demonstrate that LPI acts as a che-
moattractant, inducing the migration and inva-
sion of GPR55-expressing MDA-MB-231 breast 
cancer cells in culture. It would be interesting to 
evaluate whether this effect is produced in vivo as 
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well. We also found that GPR55 enhances the le-
vels of the metastatic markers ANGPTL4, CXCL1 
and MMP1. Growing evidences support the idea 
that tumor cells acquire genetic alterations that 
can be encompassed in a gene-expression pro-
file or signature, that in turn can predict the risk 
of metastatic recurrence and favor organ speci-
fic metastases (Nguyen and Massagué, 2007). 
For example, some genes such us epiregulin, 
CXCL1, MMP1, MMP2, the cell adhesion molecu-
le SPARC, VCAM1 receptor and ANGPTL4 have 
been implicated in breast cancer metastasis to 
the lungs (Minn et al., 2005; Padua et al., 2008). 
The modulation of a specific set of metastasis-
related genes by GPR55 suggests that GPR55 
could favor a gene profile that confers cancer 
cells a higher and probably organ-specific metas-
tatic potential.
We and others (Ford et al., 2010) have found 
that GPR55 is abundantly expressed in the highly 
metastatic breast cancer cell line MDA-MB-231 
compared with the poorly metastatic breast can-
cer cells MCF-7, BT474 and SKBr3. Moreover, 
we found that GPR55 levels are higher in basal-
like breast cancer cell lines than in luminal cells 
(Discussion figure 2). According to their molecular 
portraits, breast cancer can be classified into five 
groups: estrogen receptor positive (ER+), that is 
divided into luminal A and luminal B; HER-2 positi-
ve, characterized by the overexpression of Erbb2; 
basal-like, and normal breast-like tumors (Perou 
et al., 2000). Basal-like breast cancers, among 
other features, are characterized by an increa-
sed expression of genes associated with motility 
and invasion and, consequently, patients with this 
type of tumors present shorter overall metastasis-
free survival (Bertucci et al., 2012). Our data su-
ggest a connection between GPR55 expression 
and the basal genotype that is especially impor-
tant due to the lack of efficient therapies for these 
patients. If confirmed in a relevant number of cell 
lines and human samples, GPR55 would turn into 
a new target for the management of these highly 
aggressive tumors.
Involvement of GPR55 in other hallmarks 
of cancer: sustained angiogenesis and altered 
immune surveillance
Although there is no solid evidence demons-
trating the involvement of GPR55 in other hall-
marks of cancer, it is tempting to speculate that 
this receptor may play a role in tumor angioge-
nesis and anti-tumor immune surveillance. As 
described in the Introduction, GPR55 is expres-
sed in endothelial cells (Henstridge et al., 2011). 
Activation of GPR55 in human microvasculature 
endothelial cells (HMVEC) stimulates endothelial 
proliferation and migration, upregulates VEGF 
and induces tube formation in vitro, all of them 
important events during angiogenesis (Zhang et 
al., 2010). These results indicate that GPR55 par-
ticipates in the control of the angiogenic process 
and suggest that it may also modulate tumor-re-
lated angiogenesis. In our glioblastoma xenograft 
studies we observed no differences in vasculari-
zation of tumors from cells expressing high or low 
levels of GPR55, but these results do not allow 
ruling out a role of GPR55 in tumor angiogenesis. 
For example, in our experimental model, GPR55 
knock-down was specifically directed to human 
tumor cells and did not affect the expression of 
the receptor in mouse endothelial cells, which are 
the main responsible for the neovascularization of 
tumors. Additionally, we found that GPR55 modu-
lates the levels of MMP1. It has been described 
that this metalloproteinase can activate PAR1 re-
ceptors on endothelial cells, inducing their prolife-
ration, migration and neoangiogenesis (Goerge et 
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al., 2006; Pei, 2005).
Increasing evidence points to a crucial role of 
the tumor microenvironment, mainly composed 
by stromal and immune cells, on tumor progres-
sion and aggressiveness. GPR55 is expressed in 
immune cells and tissues (Henstridge et al., 2011) 
and different studies have reported an important 
role of the receptor in immune responses. Thus, 
GPR55 modulates the response to inflammatory 
and neuropathic pain by controlling the levels 
of various cytokines (Staton et al., 2008). It also 
promotes chemotaxis and regulates ROS pro-
duction in neutrophils (Balenga et al., 2011). It 
might also have anti-inflammatory effects. Thus, 
inflammatory agents induce the release of NGF in 
mast cells, which is blocked by GPR55 activation 
(Cantarella et al., 2011). It is well described that 
TPA topical application in the mouse skin indu-
ces, besides hyperproliferation, local inflamma-
tion (Abel et al., 2009). Results presented in this 
Thesis show that GPR55-deficient mice present a 
reduced number of inflammatory infiltrating cells 
in the dermis. Moreover, the increased levels of 
inflammatory cytokines produced by TPA topical 
application were not observed in GPR55 KO mice 
(Discussion figure 1). Together, these data sug-
gest that the pro-oncogenic properties of GPR55 
may include the alteration of the tumor-associa-
ted inflammatory response. 
GPR55 participates in the effect of THC on 
cancer cell proliferation 
Although the best characterized ligand of 
GPR55 is LPI, it has been reported that some 
cannabinoids are able to engage and activate this 
receptor (Baker et al., 2006; Sharir and Abood, 
2010). It is also well described that cannabinoids 
from different origins (synthetic, endogenously 
produce and plant-derived) exert anti-tumoral 
effects in vitro and in vivo (Hermanson and Mar-
nett, 2011; Velasco et al., 2012). Most of these 
effects are produced by activation of CB1 and 
CB2 cannabinoid receptors, but the involvement 
of additional targets cannot be ruled. Thus, we 
analyzed the potential participation of GPR55 in 
the effect of THC on cancer cell proliferation. Spe-
cifically, GPR55 seems to mediate the proliferative 
effect induced by low concentrations of THC. In-
terestingly, this participation is not restricted to a 
specific type of tumor cell and it was demonstra-
ted in breast cancer cells, glioblastoma cells (this 
Thesis) and pancreatic adenocarcinoma cells (our 
group’s unpublished data). Whether THC is able 
to bind and activate GPR55 is still a controversial 
issue (Sharir and Abood, 2010). Our data suggest 
that THC does not release intracellular Ca2+ via 
GPR55. Preliminary results point to the existen-
ce of different GPR55/CB1 interaction status that 
may lead to the activation of different signaling 
pathways and, therefore, to the different biological 
responses (enhancement vs inhibition of cell pro-
liferation) produced by different concentrations 
of the same compound (THC). The relevance of 
GPCR heteromers in regulating cell signaling has 
been previously reported. In the context of canna-
binoid receptors, several authors have confirmed 
that CB1/dopamine receptors, CB1/opioid recep-
tors (Pertwee et al., 2010), CB1/CB2 (Callen et al., 
2012), CB1/GPR55 (Kargl et al., 2012) and CB2/
GPR55 (Balenga et al., 2011) heteromers signal 
through different signaling pathways than each 
individual receptor. Experiments are currently in 
progress to confirm the functional interaction of 
CB1 and GPR55 in cancer cells and to determine 
if that interaction is produced by physical contact 
of the receptors or by a downstream signaling 
crosstalk. The participation of CB2 in this complex 
scenario is also being tested.
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An alternative possible mechanism of GPR55 
activation by THC involves heterotrimeric G pro-
tein-independent pathways. The most studied 
alternative signaling pathway is mediated by 
β-arrestin (Maurice et al., 2011). Two reports have 
used the recruitment of β-arrestin to determine re-
ceptor activation by THC, though the results are 
controversial. One of them did not find β-arrestin 
recruitment after THC treatment of HEK293 cells 
overexpressing GPR55 (Kapur et al., 2009), while 
the other showed that THC behaved as a weak 
agonist in this assay (Yin et al., 2009). Further 
experiments should be carried out to determi-
ne whether THC activates GPR55 and induces 
β-arrestin signaling. This has been however de-
monstrated in closely related GPCRs. For exam-
ple, CB1 mediates downstream signaling through 
β-arrestin, thereby activating Src, MEK1/2 and 
ERK (Ahn et al., 2013); LPA induces NFκB activa-
tion and IL-6 expression through β-arrestin (Sun 
and Lin, 2008); and CB2 upregulates the serotonin 
receptor 5-HT2A by a mechanisms that requires 
β-arrestin (Franklin et al., 2012). It would be in-
teresting to analyze, for example, whether GPR55 
(via β-arrestin) modifies the expression levels of 
classical cannabinoid receptors. 
Although our results on the involvement of 
GPR55 in the biphasic effect of THC on cancer 
cell proliferation are still very preliminary, they re-
present the first approach to unmask the molecu-
lar bases underlying cannabinoid bell-shaped ac-
tions in cancer cells, which have been extensively 
documented in other various biological settings. 
For example, biphasic cannabinoid effects have 
been reported on fear coping strategies (Metna-
Laurent et al., 2012), visual accuracy (McLaughlin 
et al., 2005), anxiety (Rey et al., 2012) or feeding 
behaviors (Sulcova et al., 1998). In these proces-
ses, at least part of the dual action of cannabi-
noids relies on the selective binding of different 
doses of the drug to activatory/glutamatergic or 
inhibitory/gabaergic neuronal terminal (Belloc-
chio et al., 2010; Rey et al., 2012). This provides 
another line of support to the exciting notion that 
different pools of a cetain GPCR located on diffe-
rent cell subpopulations can signal in a different 
manner, thus further increasing the complexity of 
these fascinating signaling platforms.
 
General Discussion
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Results obtained in this Thesis allow us to conclude that:
1. The orphan receptor GPR55 confers pro-oncogenic advantages on tumor cells in vitro and 
in mouse cancer models by promoting their proliferation, migration and invasion. Consequently, 
elevated expression of GPR55 in human tumors is associated to high aggressiveness and poor 
prognosis.
2. GPR55 participates in the proliferative effect of THC on cancer cells as produced by low 
concentrations of the cannabinoid. 
Together, these conclusions point to GPR55 as a new biomarker with possible prognostic value, 
and as a new therapeutic target in oncology. 
CONCLUSIONS
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CONCLUSIONES
Los resultados obtenidos en esta Tesis nos permiten concluir que:
1. El receptor huérfano GPR55 proporciona ventajas pro-oncogénicas a las células tumorales, 
induciendo su proliferación, migración e invasión tanto in vitro como in vivo. En consecuencia, nive-
les elevados de GPR55 en tumores humanos se correlacionan con una mayor agresividad tumoral 
y un peor pronóstico de los pacientes.  
2. GPR55 participa en el efecto del THC sobre la proliferación de células tumorales, concre-
tamente en el aumento de la proliferación inducido por bajas concentraciones del cannabinoide.
En conjunto, nuestros datos sugieren que GPR55 podría ser una nueva herramienta con valor pro-
nóstico y una nueva diana terapéutica en cáncer.
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